Site Map

Home

Patients & Caregivers

• Basics
  
• Pre-Transplant Process
  
• Transplant Process
  
• Post-Transplant Process
  
• Planning for a Transplant
  
• Finances
  
• Patient Handouts
  

Clinical Trials

• 1581 - Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients with STI-571 Responsive Ph+ Acute Leukemia - Multi-Center Trial
  
• 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial
  
• 1992 - A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia
  
• A Multicenter Phase II Trial of Bortezomib (Velcade), Melphalan, and Dexamethasone (V-MD) in Patients with Symptomatic AL-Amyloidosis or Light Chain Deposition Disease
  
• A Phase 2 Open Label Mulitcenter Clinical Study of the Safety and Efficacy of SNS-595 Injection in Patients ≥ 60 Years of Age with Previously Untreated Acute Myeloid Leukemia
  
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of the Safety and Efficacy of Orbec® (Oral Beclomethasone 17,21 - Dipropionate) in Conjunction with Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients with Gastrointestinal Graft Vs. Host Disease
  
• A Treatment Guideline for High-Dose Melphalan with Autologous Hematopoietic Stem Cell Reconstitution for Primary Systemic Amyloidosis
  
• Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial
  
• Cyclophosphamide and Antithymocyte Globulin, With or Without Total Body Irradiation, Followed By Allogeneic Hematopoietic stem Cell Transplantation For Severe Aplastic Anemia
  
• Fludarabine and Once-Daily Intravenous Busulfan Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation
  
• High Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplant As Rescue Therapy for Multiple Myeloma
  
• Phase 3 Open-Label Randomized Study of Amonafide L-Malate in Combination with Cytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML)
  
• Rocky Mountain Blood and Marrow Transplant Program Busulfan and Cyclophosphamide Followed By Hematopoietic Stem Cell Transplantation:
  
• Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants
  
• Tacrolimus And Mycophenolate Mofetil As Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation For Recipients of HLA-Matched Family or Unrelated Donor Hematopoietic Cell Transplants.
  
• Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol
  
• Treatment Of Hematologic Malignancies With High-Dose Chemo-Radiotherapy Followed By Single-Unit Or Double-Unit Cord Blood Transplantation: A Phase II Study
  
• Treatment of Non-Hodgkin Lymphoma with High-Dose Carmustine, Etoposide, Cytarabine, and Cyclophosphamide (BEAC) or Melphalan (BEAM) Followed by Autologous Peripheral Blood Progenitor Cells Standard Care Treatment Protocol
  
• Treatment of Non-Hodgkin Lymphoma with High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Followed by Allogeneic Marrow or Peripheral Blood Stem Cell Transplantation
  
• Treatment of Relapsed or Primary Refractory Hodgkin Lymphoma with High-Dose CBV Followed by Autologous Peripheral Blood Progenitor Cell Rescue
  

Program Statistics

Referrals

Continuing Care

Diseases

• Acute Lymphocytic Leukemia (ALL)
  
• Acute Myeloid Leukemia (AML)
  
• Amyloidosis
  
• Aplastic Anemia
  
• Chronic Lymphocytic Leukemia (CLL)
  
• Chronic Myeloid Leukemia (CML)
  
• Hodgkin Lymphoma
  
• Multiple Myeloma
  
• Myelodysplastic Syndrome (MDS)
  
• Non-Hodgkin Lymphoma (NHL)
  
• Testicular Cancer
  

Patient Stories

• Bob Heykoop
  
• Janice Gangl
  
• Leslie Szabo
  
• Maggie Brunner
  
• Wayne Marrone
  

News

• 
  
• Investigators publish new data in the report "Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia."
  
• Mozobil™ Approved for Stem Cell Mobilization in NHL and MM Patients
  
• New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
  
• Novel therapies that target Rap1 could potentially be used to treat leukemias caused by BCR/ABL
  
• Protein key to control, growth of blood cells
  
• Sprycel® (Dasatinib) Confirmed Effective for Gleevec-Resistant Patients with Chronic Myeloid Leukemia (CML)
  
• Surgery Earlier In Life Reduces Risk of Testicular Cancer Among Males with Undescended Testis
  
• The Leukemia & Lymphoma Society and Provid Pharmaceuticals announce collaboration on treatment for acute myelogenous leukemia
  
• 'Mini transplant' patients' outcomes similar using related and unrelated donor cells
  
• 'Modular' leukemia drug shows promise in early testing
  
• 2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate (Atiprimod) induced apoptosis in multiple myeloma (MM) cells
  
• 2008 SF Leukemia Cup Regatta - Sailing for Leukemia
  
• 3-drug combination 'extremely promising' as first-line therapy for multiple myeloma
  
• 3-substituted benzamide derivatives could be used to treat chronic myeloid leukemia (CML)
  
• A case of donor cell-derived acute leukemia occurred following umbilical cord blood transplantation
  
• A denaturing high-performance liquid chromatography (DHPLC) assay could be used to identify NPM1 mutations in leukemia
  
• A denaturing high-performance liquid chromatography (DHPLC) assay could be used to identify NPM1 mutations in leukemia
  
• A Disease Affecting White Blood Cells, the Body’s Infection Fighters
  
• A faster way to recover from chemotherapy and marrow transplant
  
• A higher risk of childhood leukemia, particularly of acute lymphoblastic leukemia (ALL), was linked to high magnetic field (MF) exposure
  
• A miR boost enables acute leukemia cells to mature
  
• A molecular-based mechanism for restriction of the leukemic phenotype to the CD4+ T cell subtype was described
  
• A new chronic myeloid leukemia (CML) staging system was proposed
  
• A new chronic myeloid leukemia (CML) staging system was proposed
  
• A new chronic myeloid leukemia (CML) staging system was proposed
  
• A new chronic myeloid leukemia (CML) staging system was proposed
  
• A new erythroblastic leukemia cell line revealed
  
• A new study, "Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self," is now available
  
• A new study, "B-1 B cells: development, selection, natural autoantibody and leukemia," is now available
  
• A new study, "B-1 B cells: development, selection, natural autoantibody and leukemia," is now available
  
• A new study, "B-1 B cells: development, selection, natural autoantibody and leukemia," is now available
  
• A new study, "Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14)," is now available
  
• A new study, "Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14)," is now available
  
• A new study, "Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up
  
• A new study, "Multiple pathways contribute to the hyperproliferative responses from truncated granulocyte colony-stimulating factor receptors," is now available
  
• A new study, "One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near,&
  
• A new study, "Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan," is now available
  
• A new study, "p21 delays tumor onset by preservation of chromosomal stability," is now available
  
• A new study, "The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells," is now available
  
• A novel intradermal idiotype vaccine elicited specific immune responses in patients with advanced B-cell lymphoma despite profound immunosuppression
  
• A potential new way to make a good anti-leukemia drug even better
  
• A recent study from Canada has reported that the TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells
  
• A report, "End points to establish the efficacy of new agents in the treatment of acute leukemia," is newly published data in Blood
  
• A report, "End points to establish the efficacy of new agents in the treatment of acute leukemia," is newly published data in Blood
  
• A report, "End points to establish the efficacy of new agents in the treatment of acute leukemia," is newly published data in Blood
  
• A report, "Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia," is newly published data in International Journal of Hematology
  
• A report, "The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid," is newly published data in The Journal of Virology
  
• A researcher reviews vaccination for leukemia in a recent issue of Biology of Blood and Marrow Transplantation
  
• A set of 7 genes have been identified that can be used to monitor minimal residual disease in pediatric acute myeloid leukemia
  
• A set of 7 genes have been identified that can be used to monitor minimal residual disease in pediatric acute myeloid leukemia
  
• A set of 7 genes have been identified that can be used to monitor minimal residual disease in pediatric acute myeloid leukemia
  
• A severe combined immunodeficient mouse model enables rapid evaluation of treatments for multiple myeloma
  
• A simplified flow cytometric assay was developed that could identify a high proportion of children with acute lymphoblastic leukemia (ALL) who would have an excellent early treatment response and a high likelihood of cure
  
• A simplified flow cytometric assay was developed that could identify a high proportion of children with acute lymphoblastic leukemia (ALL) who would have an excellent early treatment response and a high likelihood of cure
  
• A study by cancer researchers reveals that a new strain of mice offers the first real animal model for an incurable form of chronic leukemia and should greatly aid the development of new drugs for the disease
  
• A triple purge strategy eliminates chronic myelogenous leukemia cells from autografts
  
• A triple purge strategy eliminates chronic myelogenous leukemia cells from autografts
  
• Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology
  
• Abbott introduces CE-marked DNA tests in Europe to detect leukemia
  
• AC133 positive leukemia cells could be prognosticated by expression of the myeloperoxidase (MPO) gene
  
• AC133 positive leukemia cells could be prognosticated by expression of the myeloperoxidase (MPO) gene
  
• According to a study from Australia, C-II amyloid fibrils are bound by high density lipoproteins
  
• According to a study from France, chronic lymphocytic leukemia (CLL) cell survival is promoted by high Mda-7 expression
  
• According to a study from Germany, BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells
  
• According to a study from Germany, gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia (CML) blast crisis
  
• According to a study from Japan, suppressor of cytokine signaling-1 expression by infectivity-enhanced adenoviral vector inhibits IL-6-dependent proliferation of multiple myeloma (MM) cells
  
• According to a study from the Netherlands, signal transducer and activator of transcription 5 (STAT5)-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBP alpha
  
• According to a study from the United States, consolidation of high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compa
  
• According to a study from the United States, consolidation of high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compa
  
• According to a study from the United States, leukemia-associated gain-of-function mutation affects interleukin-3 (IL-3) signaling
  
• According to a study from the United States, leukemia-associated gain-of-function mutation affects interleukin-3 (IL-3) signaling
  
• According to a study from the United States, phosphoproteomic analysis of acute myeloid leukemia (AML) cell lines identifies leukemic oncogenes
  
• According to a study from the United States, phosphoproteomic analysis of acute myeloid leukemia (AML) cell lines identifies leukemic oncogenes
  
• According to recent research from France, human T-cell leukemia virus type 1 (HTLV-1) infected cell fusion with dendritic cells (DCs) is facilitated by DC-specific ICAM-3-grabbing nonintegrin (DC-SIGN)
  
• According to recent research from the United States, a human T-cell leukemia virus type 1 (HTLV-1) motif participates in Gag targeting and particle release
  
• According to recent research from the United States, c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma
  
• According to recent research published in the journal Clinical and Experimental Dermatology, malignant melanoma (MM) expresses endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF)
  
• According to recent research published in the journal Molecular Cancer Therapeutics, myeloma cell caspase-dependent apoptosis and cell cycle inhibition is induced by the IMP dehydrogenase (IMPDH) inhibitor mycophenolate mofetil (MMF)
  
• According to recently published research from the People's Republic of China, inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis
  
• According to recently published research from the United States, human leukemic cells are affected by a synthetic triterpenoid, C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO-Me)
  
• Activated M-Ras expression in hematopoietic stem cells initiates leukemogenic transformation
  
• Activation of LYN kinase is associated with imatinib-resistance in CML patients
  
• Acute (AML) and chronic myeloid leukemia (CML) pathogenesis could be linked to abnormal expression of the programmed cell death 5 (PDCD5) gene
  
• Acute lymphoblastic leukemia (ALL) cells respond to thalidomide analogue CC-4047
  
• Acute lymphoblastic leukemia (ALL) could be treated by short-course high-dose methylprednisolone (HDMP) instead of prednisolone
  
• Acute lymphoblastic leukemia (ALL) poor prognosis could be linked to ASPP1 gene promoter expression
  
• Acute lymphoblastic leukemia (ALL) poor prognosis could be linked to ASPP1 gene promoter expression
  
• Acute lymphoblastic leukemia (ALL) poor prognosis could be linked to ASPP1 gene promoter expression
  
• Acute lymphoblastic leukemia cells respond to thalidomide analogue CC-4047
  
• Acute lymphoblastic leukemia poor prognosis predicted by Aven overexpression
  
• Acute lymphoblastic leukemia prognosticated by CALCA promoter hypermethylation
  
• Acute lymphoblastic leukemia remission is likely when lymphangiogenesis factor is absent
  
• Acute myelogenous leukemia (AML) could be linked to JAK2 V617F mutation
  
• Acute myeloid leukemia (AML) could be managed on an outpatient basis
  
• Acute myeloid leukemia (AML) could be prognosticated by the size of FLT3 internal tandem duplication (FLT3/ITD)
  
• Acute myeloid leukemia (AML) is detected by angiogenesis biomarkers
  
• Acute myeloid leukemia (AML) patients with KIT-D816 mutations were associated with poor prognosis
  
• Acute myeloid leukemia (AML) patients with KIT-D816 mutations were associated with poor prognosis. "Mutations in codon D816 of the KIT gene represent a recurrent genetic alteration in AML
  
• Acute myeloid leukemia (AML) patients with normal cytogenetics could be prognosticated by BAALC expression
  
• Acute myeloid leukemia (AML) was associated with cyclin A1 expression
  
• Acute myeloid leukemia (AML) with t(8;21)(Q22;q22) is linked to frequent expression of B cell-specific activator protein (BSAP), whereas PAX5 silencing is not required for myeloid differentiation
  
• Acute myeloid leukemia (AML) with t(8;21)(Q22;q22) is linked to frequent expression of B cell-specific activator protein (BSAP), whereas PAX5 silencing is not required for myeloid differentiation
  
• Acute myeloid leukemia and myelodysplastic syndrome find new target of 11q amplification in GAB2
  
• Acute myeloid leukemia cell beta-catenin expression predicts poor prognosis
  
• Acute myeloid leukemia infants have high incidence of t(7;12)(q36;p13)
  
• Acute myeloid leukemia is detected by angiogenesis biomarkers
  
• Acute myeloid leukemia patients 50 years of age or older responded to induction therapy
  
• Acute myeloid leukemia progression prognosticated by serum levels of sCD137
  
• Acute myeloid leukemia was associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque
  
• Acute myeloid leukemia was associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque
  
• Acute myeloid leukemia-associated MLL partial tandem duplications persist lifelong
  
• Adding Radioimmunotherapy To Chemo May Help Patients With Lymphoma
  
• Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
  
• Addition of Zevalin(R) to Chemotherapy Effective for Follicular NHL
  
• Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for active immunotherapy of T cell lymphoma
  
• Administration of short course, high dose methylprednisolone (HDMP) might improve endothelial dysfunction caused by acute lymphoblastic leukemia (ALL)
  
• Adolescent survivors of childhood acute lymphoblastic leukemia (ALL) reported difficulties in overcoming psychological and physical pain
  
• Adolescent survivors of childhood acute lymphoblastic leukemia (ALL) reported difficulties in overcoming psychological and physical pain
  
• Adult acute lymphoblastic leukemia patients with dic(7:9) demonstrate a consistent phenotype
  
• Adult acute megakaryocytic leukemia (FAB M7 AML) was confirmed to have a poor prognosis
  
• Adult B-lineage acute lymphoblastic leukemia (ALL) could be managed by a flow cytometric approach to minimal residual disease (MRD) monitoring
  
• Adult survivors of childhood cancer have lower bone mineral density
  
• Adult survivors of childhood leukemia exercise less, worsening high risk for obesity and illness
  
• Adult T-cell leukemia (ATL) could be treated by curcumin
  
• Adult T-cell leukemia/lymphoma (ATLL) progression was linked to the down-regulation of ASY/Nogo transcription
  
• Advanced Hodgkin lymphoma (HL) patients did not benefit more from radiotherapy (RT) than consolidation chemotherapy (CT) after a doxorubicin-induced CR
  
• Advanced therapy offers cure for relapsed cancer patient
  
• Advances in the reduction of mortality from childhood acute myeloid leukemia (AML) were reviewed
  
• Advances in the reduction of mortality from childhood acute myeloid leukemia (AML) were reviewed
  
• Advances in the Treatment of Aggressive Non-Hodgkin’s Lymphoma
  
• Aegera Therapeutics Acquires Clinical Stage Oncology Company and Closes Concurrent Financing
  
• Aggressive form of lymphoma on the rise: U.S. study
  
• AIDS-related non-Hodgkin leukemia outcome is associated with Epstein-Barr viral load in whole blood
  
• Alexion launches EXPLORE study for severe anemia disorder
  
• Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
  
• Allo-SCT using cord blood or matched-sibling donors comparable in advanced Hodgkin lymphoma
  
• Allogeneic hematopoietic stem cell transplantation favors altered hypothalamic dopaminergic tone
  
• Allogeneic stem cell transplantation using umbilical cord blood or matched-sibling donors is comparable in adults with high-risk advanced Hodgkin's lymphoma
  
• Allogeneic Stem Cell Transplants May Be Best Option for Cutaneous T-Cell Lymphomas
  
• Allos Therapeutics Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
  
• Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
  
• Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma
  
• Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
  
• Almac Teams up with the Leukemia and Lymphoma Society
  
• Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
  
• AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data
  
• Amyloidosis, scarring of pulmonary vein myocardial sleeves is common in elderly
  
• An autologous vaccine expressing transgenic human CD40L and IL-2 provides immunotherapy of high-risk acute leukemia
  
• An Interactive Dialog on Myeloma, Lymphoma and Leukemia: Clinical Integration of Recent Advances was held in Scottsdale on May 20, 2006
  
• An orally active proteasome inhibitor induced apoptosis in multiple myeloma (MM) cells
  
• Analysis shows revlimid plus dexamethasone increases overall survival in multiple myeloma patients
  
• Angiogenesis cytokines accelerate endothelial-like cell differentiation
  
• Annual Mammography Alone Not Sufficient for Young Hodgkin’s Survivors
  
• AnorMED completes enrollment in phase III trial for Mozobil
  
• ANORMED COMPLETES ENROLLMENT IN PHASE III TRIAL FOR MOZOBIL IN STEM CELL TRANSPLANT IN MULTIPLE MYELOMA
  
• Antiestrogenic therapies proposed to treat solid cancers and multiple myeloma
  
• Antigen identified as possible immunotherapy for myeloid leukemias
  
• Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201
  
• Antisoma Starts Phase II Trial of AS1411 in Acute Myeloid Leukaemia
  
• Apoptotic gene expression profiled in chronic lymphocytic leukemia
  
• Approval summary of nelarabine for T cell lymphoblastic leukemia and lymphoma is released
  
• ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Inhibition of All Known Variants of the CML Target Protein Bcr-Abl
  
• Arsenic Compound Improves Survival of Adults with Uncommon Form of Leukemia
  
• Arsenic trioxide boosts survival in leukemia
  
• Arsenic-based therapy shown to help eradicate leukemia-initiating cells
  
• ASCO Patient Guide: Bisphosphonates for Multiple Myeloma
  
• ASCO Presentation Highlights Memgen's ISF35 Anti-Cancer Activity in Chronic Lymphocytic Leukemia
  
• Atypical myeloproliferative disorders were discussed
  
• Atypical myeloproliferative disorders were discussed
  
• Australian scientists unravel Leukaemia link
  
• Autologous dendritic cells generated from leukemic blasts show promise as immunotherapy for patients with acute myeloid leukemia
  
• Autologous dendritic cells pulsed with necrotic tumor lysate generated in vitro B-CLL-specific HLA class I restricted CTL responses
  
• Autologous Stem Cell Transplantation Effective for Relapsed or Refractory Hodgkin’s Lymphoma
  
• Autologous stem cell transplantation safe and effective in myeloma patients
  
• Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?
  
• Azerra MAA Accepted by EMEA for CLL
  
• B cell chronic lymphocytic leukemia response to nutlin-3 should be studied
  
• B cell lymphoma could be linked to inactivation of the PR domain containing 1 with zinc finger domain (PRDM1)/B lymphocyte-induced maturation protein 1 (BLIMP1) gene
  
• B chronic lymphocytic leukemia cell interleukin production involves RANKL/RANK
  
• B-cell Chronic Lymphocytic Leukemia (B-CLL): Expanded Labeling for MabCampath in Europe
  
• B-cell chronic lymphocytic leukemia (CLL) finds hope in new therapeutic strategy that targets the Mdm2-p53 interaction
  
• B-cell depletion may enhance antitumor immune responses by decreasing IL-10 production from B cells
  
• B-cell lymphoma could be examined by automated analysis of fluorescence in situ hybridization
  
• B-MS boosts biologics pipeline with PDL BioPharma deal
  
• B-precursor childhood acute lymphoblastic leukemia (ALL) could be linked to perforin (PRF1) polymorphism A91V but requires further study
  
• Bayer HealthCare Pharmaceuticals (BAY) Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
  
• BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia
  
• BCR-ABL transcript level patterns after allograft is variable in chronic myeloid leukemia
  
• BCR-ABL transcript level patterns following stem cell transplantation is variable in patients with Philadelphia chromosome-positive chronic myeloid leukemia
  
• BCR-ABL transcript level patterns following stem cell transplantation is variable in patients with Philadelphia chromosome-positive chronic myeloid leukemia
  
• BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
  
• Belinostat in its first pivotal trial in PTCL
  
• Best and brightest leukemia researchers receive $1-million from Cole Foundation
  
• Better alternative to HLA typing as a genetic test for abacavir hypersensitivity syndrome reported
  
• Bexarotene is useful in the treatment of cutaneous T-cell lymphoma
  
• Bik/NBK accumulation correlates with apoptosis induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors
  
• BIOCRYST INITIATES ENROLLMENT IN PIVOTAL TRIAL OF FORODESINE HCL IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
  
• BioCryst Pharmaceuticals, Inc., (BCRX) announced that it has initiated a pivotal trial of its lead oncology drug, Fodosine, in the treatment of patients with relapsed or refractory T-cell leukemia/lymphoma
  
• BioCryst Pharmaceuticals, Inc., (BCRX) announced the receipt of a Special Protocol Assessment (SPA) letter from the U.S. Food and Drug Administration (FDA) for Fodosine (forodesine hydrochloride)
  
• BioCryst Pharmaceuticals, Inc., (BCRX) provided an informational update summarizing highlights from an oral presentation related to the clinical development of forodesine hydrochloride (formerly referred to as Fodosine)
  
• BIOCRYST RECEIVES SPECIAL PROTOCOL ASSESSMENT FOR PIVOTAL TRIAL OF ORAL FODOSINE IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA
  
• Bioenvision Provides Evoltra (clofarabine) Regulatory Update
  
• Biofeedback therapy helps some people control aspects of their body
  
• Blood cancer breakthroughs presented
  
• Blood Stem Cells Originate in the Placenta
  
• Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis
  
• Bone marrow stem cell co-transplantation prevents embryonic stem cell transplant-associated tumors
  
• Bone Pain Can Be A Sign Of Myeloma - Patients And Doctors Join Forces To Raise Awareness Of Early Myeloma Diagnosis
  
• Bortezomib (Velcade) in Combo Scores For Initial Myeloma Treatment
  
• Bortezomib causes severe pulmonary complications in Japanese patients
  
• Bortezomib for injection shows positive results in newly diagnosed multiple myeloma patients
  
• Bosutinib: A New Kinase Inhibitior for Treatment of Philadelphia Chromosome Positive Leukemia
  
• Breast-feeding of more than 6 months could prevent childhood lymphoid malignancies, especially for acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML)
  
• Breastfeeding patterns were not linked to the risk of childhood acute lymphoblastic leukemia (ALL)
  
• Callisto Pharmaceuticals study of anti-leukemia drug L-Annamycin is expanded
  
• Can cancer drugs combine forces?
  
• Cancer drug shows promise against graft vs. host disease
  
• Cancer Researchers at the University of Pennsylvania Discover What Makes Lymphomas Tick
  
• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate documented
  
• Cases of chronic myelogenous leukemia and rheumatic disease linked
  
• Causes of male infertility investigated
  
• CD38 expression correlates with cell mutation status in chronic lymphocytic leukemia according to a study from the Netherlands
  
• Ceflatonin receives U.S. FDA orphan drug designation for treatment of chronic myeloid leukemia
  
• CELATOR PHARMACEUTICALS ENROLLS FIRST PATIENT IN ITS PHASE 2 STUDY OF CPX-351 IN ACUTE MYELOID LEUKEMIA IN FIRST RELAPSE
  
• Celgene Corporation (CELG) announced that the European Medicines Agency (EMEA) has accepted for review the company's marketing authorization application (MAA) for lenalidomide in the treatment of multiple myeloma
  
• Cell Genesys Provides Update on Clinical Program for GVAX Immunotherapy for Leukemia
  
• Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
  
• Cell Therapeutics CHOP-Zevalin Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
  
• Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
  
• Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
  
• Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
  
• Cell-penetrating peptide are a vector for tracking mesenchymal stem cells
  
• Cellular transformation by human T-cell leukemia virus type 1 (HTLV-1) could be associated with TAX
  
• Cephalon Announces Plans For New NDA Filing For TREANDA(R)
  
• Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma
  
• Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
  
• Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
  
• Ceplene(R) Receives Positive European Opinion for Approval From CHMP for Acute Myeloid Leukemia (AML)
  
• Challenges to identifying genetic determinants of pediatric cancers were discussed
  
• Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia (ALL) were analyzed
  
• Changes in multiple myeloma epidemiology in last 30 years reviewed
  
• ChemGenex Announces Positive Preliminary Data From Phase 2/3 Clinical Trial of Ceflatonin® at International Conference
  
• ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML
  
• ChemGenex launches multinational phase 2/3 study for CML patients with T315I mutation
  
• ChemGenex Pharmaceuticals (ASX: CXS) (NASDAQ: CXSP) announced that positive clinical results supporting the development of Ceflatonin(R) in patients with chronic myeloid leukemia (CML)
  
• ChemGenex Pharmaceuticals (ASX: CXS) (NASDAQ: CXSP) announced that positive clinical results supporting the development of Ceflatonin(R) in patients with chronic myeloid leukemia (CML)
  
• ChemGenex Pharmaceuticals (CXS; CXSP) announced that it has launched a new multinational phase 2/3 study evaluating the use of Ceflatonin (homoharringtonine, HHT) in patients with chronic, accelerated and blast-phase chronic myeloid leukemia (CML)
  
• ChemGenex Pharmaceuticals Limited (CXS and CXSP) announced the presentation of new clinical data supporting the use of Ceflatonin (homoharringtonine or HHT) as a treatment for chronic myeloid leukemia (CML) patients who have developed resistance to Gleeve
  
• ChemGenex Pharmaceuticals Limited (CXS and CXSP) announced the recent publication of two clinical research papers that support the expansion of the clinical development of Ceflatonin to include treatment of both newly diagnosed acute myeloid leukemia (AML
  
• ChemGenex Pharmaceuticals Limited announced the publication of preclinical research supporting the expansion of its clinical development of Ceflatonin to include treatment of acute myeloid leukemia (AML) patients in addition to chronic myeloid leukemia (C
  
• ChemGenex presents data on Ceflatonin for treating CML patients resistant to Gleevec
  
• ChemGenex publishes two new clinical studies supporting Ceflatonin beyond CML to other leukemias
  
• ChemGenex Seeking Partners to Sell Leukemia Treatment
  
• ChemGenex teams with MolecularMD to identify CML patients with T315I drug resistance mutation
  
• CHEMGENEX'S OMACETAXINE DEMONSTRATES ACTIVITY IN CML PATIENTS WHO HAVE FAILED THERAPY WITH MULTIPLE TYROSINE KINASE INHIBITORS
  
• Chemoimmunotherapy effective in elderly with chronic lymphocytic leukemia
  
• Chemotherapy plus Radiation Recommended as Standard of Care in Early Hodgkin’s
  
• Childhood acute myeloid leukemia (AML) survival was worse in Hispanic and black children than white children
  
• Childhood cancer survival prognostic factors identified
  
• Childhood Leukemia And Lymphoma Survivors Have Elevated Risk Of Second Cancers
  
• Childhood leukemia risk could be linked to birth weight, maternal weight, and factors that influence abnormal fetal growth patterns
  
• Childhood Leukemia Survivors Have Decreased Height in Adulthood
  
• Childhood lymphoid malignancies protected against by breast-feeding of more than 6 months
  
• Children and young people show elevated leukaemia rates near nuclear facilities
  
• Children's Hospital researcher leads multi-pronged attack on infant leukemia
  
• CHMP Awards Positive Opinion for Myelodysplastic Syndrome Drug
  
• Chronic lymphocytic leukemia biology influenced by p53 polymorphisms
  
• Chronic lymphocytic leukemia cell survival is promoted by high Mda-7 expression
  
• Chronic lymphocytic leukemia displays a proangiogenic component
  
• Chronic lymphocytic leukemia displays a proangiogenic component
  
• Chronic lymphocytic leukemia treatment could be treated with weekly clofarabine
  
• Chronic myelogenous leukemia patients exhibit altered bone and mineral metabolism while receiving imatinib
  
• Chronic myelogenous leukemia therapy finds new target in Janus kinase 2
  
• Chronic myeloid leukemia (CML) imatinib treatment could be enhanced by valproate
  
• Chronic myeloid leukemia (CML) patients might experience molecular remission after imatinib mesylate treatment
  
• Chronic myeloid leukemia (CML) response to imatinib could be predicted by prospective quantitation of BCR-ABL transcript
  
• Chronic myeloid leukemia developed in a patient with primary thrombocythemia (PT) and absence of BCR/ABL rearrangement
  
• Chronic myeloid leukemia patient monitoring and methods for detecting BCR-ABL transcripts outlined
  
• Chronic myeloid leukemia patients to benefit from promising new drug
  
• Chronic myeloid leukemia response to imatinib predicted by quantitation of BCR-ABL transcript
  
• cIAP2 disfunction was implicated in mucosa-associated lymphoid tissue (MALT) lymphomas
  
• CIGNA HealthCare Teams with HopeLab to Help Blast Teen Cancer
  
• Cleveland BioLabs, Inc. (CBLI) announced that through its research in the area of radiation protection, the company has discovered a unique property of its Protectans 600 series, which has lead to a major breakthrough in the stem cell arena
  
• Clinical Challenges in the Management of Acute Myeloid Leukemia: Peer-to-Peer Forums for Improving Patient Care
  
• Clinical Challenges in the Management of Acute Myeloid Leukemia: Peer-to-Peer Forums for Improving Patient Care
  
• Clinical study shows biological and clinical activity in relapsed leukemia patients
  
• Clofarabine and cytarabine induction therapy was active in acute myeloid leukemia (AML) patients 50 years of age or older, warranting further evaluation
  
• Clofarabine and cytarabine induction therapy was active in acute myeloid leukemia (AML) patients 50 years of age or older, warranting further evaluation
  
• Clofarabine and cytarabine induction therapy was active in acute myeloid leukemia (AML) patients 50 years of age or older, warranting further evaluation
  
• Clone-specific PCR assesses minimal residual disease in patients with hairy cell leukemia
  
• Clone-specific PCR assesses minimal residual disease in patients with hairy cell leukemia
  
• Clone-specific PCR assesses minimal residual disease in patients with hairy cell leukemia
  
• CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug
  
• CombiMatrix Molecular Diagnostics Launches HemeScan Ploidy Test for the Management of Acute Lymphoblastic Leukemia
  
• Combination of two novel anti-cancer agents may help fight CML resistant to current therapy
  
• Combination Therapy Effective Against Multiple Myeloma
  
• Complete remission before autografting predicts better survival in patients with advanced stage peripheral T-cell lymphoma
  
• Complex chromosomal rearrangements (CCR) were detected in patients with chronic myeloid leukemia (CML)
  
• Constitutively active STAT5b induces cytokine-independent growth of the acute myeloid leukemia-derived MUTZ-3 cell line and accelerates its differentiation into mature dendritic cells
  
• Coping was linked to survival in leukemia patients undergoing allogeneic bone marrow transplantation (BMT)
  
• Cord blood research advances have been reported from the United States and Netherlands
  
• Cord blood transplants OK for leukemia
  
• CSHL team develops mouse models of leukemia that predict response to chemotherapy
  
• CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
  
• Curacyte receives European Orphan Drug Designation for its PDE-4 inhibitor in Chronic Lymphocytic Leukemia
  
• CuraGen and TopoTarget announce initiation of first NCI-sponsored clinical trial with PXD101
  
• CuraGen and TopoTarget announce NCI-sponsored Phase II clinical trial with PXD101 for AML
  
• CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
  
• CuraGen and TopoTarget present new preclinical data on PXD101 in treating cancer
  
• CuraGen Announces Top-Line Phase II Results on Velafermin
  
• CuraGen Corporation (CRGN) and TopoTarget A/S announced that the companies have reviewed interim efficacy and safety data from the ongoing open-label trial evaluating belinostat (PXD101) monotherapy for the treatment of cutaneous T-cell lymphoma (CTCL)
  
• CuraGen Presents Update on Clinical Development Program for Belinostat
  
• Current study results from the report, "Aggressive natural killer cell leukemia: report of a Chinese series and review of the literature," have been published
  
• Current study results from the report, "Benzene exposure and risk of non-Hodgkin lymphoma," have been published
  
• Current study results from the report, "Benzene exposure and risk of non-Hodgkin lymphoma," have been published
  
• Current study results from the report, "Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma," have been published
  
• Current study results from the report, "Cardiac autonomic functions are altered in patients with acute leukemia, assessed by heart rate variability," have been published
  
• Current study results from the report, "Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide," have been published
  
• Cyclacel announces completion of enrollment in Phase 2 trial of sapacitabine in elderly AML
  
• Cyclacel expands Phase 2 sapacitabine trial in elderly AML to include patients with MDS
  
• Cyclacel Reports Phase I Sapacitabine Data in Patients with Advanced Leukemias and Myelodysplastic Syndromes at 2007 ASCO Annual Meeting
  
• Cyclacel reports survival data from phase 2 sapacitabine study in elderly patients with acute myeloid leukemia
  
• Cyclophosphamide and fludarabine could be used to treat chronic lymphocytic leukemia (CLL)
  
• Cylene Pharmaceuticals’ Ribosomal RNA Biogenesis Inhibitor, Quarfloxin (CX-3543), Enters Phase II Clinical Trial
  
• Cytogenetic response to prior IFN treatment predicts survival after AHSCT in CML
  
• Cytokinetics, Incorporated (CYTK) announced that a poster summarizing non-clinical data evaluating ispinesib (SB-715992), a novel inhibitor of the mitotic kinesin, kinesin spindle protein (KSP), in cellular models of multiple myeloma
  
• Daisies lead scientists down path to new leukemia drug
  
• Dasatinib shows high early response rate as first treatment for chronic myelogenous leukemia
  
• Dasatinib studied in patients with leukemia and resistance or intolerance to imatinib
  
• Dasatinib targets earlier progenitors than imatinib in primary chronic myeloid leukemia
  
• Data at ASCO demonstrate potential of Velcade for injection across solid and hematological cancers
  
• Data detailed in "Establishment of an arsenic trioxide-resistant human leukemia cell line that shows multidrug resistance" have been presented
  
• Data detailed in "Findings of fluorine-18-FDG PET in extranodal origin lymphoma--in three cases of diffuse large B cell type lymphoma" have been presented
  
• Data detailed in "Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression" have been presented
  
• Data detailed in "Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression" have been presented
  
• Data From Ongoing Hematological Trials With Darinaparsin Presented at European College of Clinical Oncology Annual Meeting
  
• Data from Phase I clinical trial of Quadramet in patients with relapsed multiple myeloma presented
  
• Data from Phase II Clinical Trial of Galiximab in Combination with Rituximab in Patients with Previously Untreated Follicular Lymphoma Presented at International Conference on Malignant Lymphoma
  
• Data from University of Pennsylvania, Abramson Cancer Center advance knowledge in lymphoma therapy
  
• Data on acute myelomonocytic leukemia published by researchers at Nagoya University
  
• Data on chronic myeloid leukemia therapy reported by researchers at Institute for Medical Informatics
  
• Data on leukemia are outlined in reports from the United States and Spain
  
• Data on leukemia therapy reported by researchers at Zhejiang University, Cancer Institute
  
• Data on lymphoma immunotherapy discussed by researchers at Nagoya City University, Department of Internal Medicine
  
• Data Show Geron’s Telomerase Inhibitor Cancer Drug is Active Against Cancer Stem Cells From Multiple Myeloma Patients
  
• Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment In Patients With Follicular Lymphoma
  
• Deciphera Pharmaceuticals Announces Initation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and ALL
  
• Decision Fails Patients with Transfusion-Dependent Anemia
  
• Dehydroxymethylepoxyquinomicin (DHMEQ), a new NF-kappa B inhibitor, could induce apoptosis in chronic lymphocytic leukemia (CLL)
  
• Dehydroxymethylepoxyquinomicin (DHMEQ), a new NF-kappa B inhibitor, could induce apoptosis in chronic lymphocytic leukemia (CLL)
  
• Dehydroxymethylepoxyquinomicin (DHMEQ), a new NF-kappa B inhibitor, could induce apoptosis in chronic lymphocytic leukemia (CLL)
  
• Dendritic cell-based vaccine generated for B-cell chronic lymphocytic leukemia
  
• Dendritic cells expand Epstein-Barr-specific CD8 T cell responses more efficiently than EBV-transformed B cells
  
• Dendritic cells from multiple myeloma patients have impaired functionality
  
• Dendritic cells from patients with multiple myeloma have impaired functionality and phenotypic profile
  
• Denileukin Receives Fast-Track Approval for Treatment of Cutaneous T-Cell Lymphoma (CTCL)
  
• Denosumab was well tolerated and reduced bone resorption for at least 84 days
  
• Detection of bone marrow lesions was improved by ferumoxtran-10-enhanced MR imaging
  
• Diagnosis of secondary malignancies after successful primary treatment of malignant Hodgkin lymphoma (HL) could be difficult
  
• Different gamma/delta T clones sustain GVM and GVH effects after non-myeloablative transplantation
  
• Discovery major step forward in treating leukemia
  
• Distribution of follicular dendritic cell (FDC) in mantle cell lymphoma (MCL) could be linked to better clinical prognosis
  
• Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
  
• DNA hypomethylation occurred after 5-aza-2'-deoxycytidine (decitabine) therapy at low doses in leukemia patients
  
• DNA hypomethylation occurred after 5-aza-2'-deoxycytidine (decitabine) therapy at low doses in leukemia patients
  
• Doctors Report High Survival Rates for Hodgkin's Disease
  
• Does a 10-year 10% Continuous Complete Remission Rate for Myeloma Patients Suggest Cure?
  
• Donor isohemagglutinin is not produced in patients undergoing minor ABO incompatible umbilical cord blood transplantation
  
• Donor lymphocyte infusions effective for treatment of relapsed disease after ASCT
  
• Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma
  
• Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma
  
• Doxil® Approved for Multiple Myeloma in Combination with Velcade®
  
• Drug aids relapsed lymphoma patients
  
• Drug avoids radiation for early testicular cancer
  
• Drug combination slows the progression of treatment resistant bone marrow cancer
  
• Drug Combo Effective Against Leukemia
  
• Drug has ability to cure type of leukemia
  
• Drug resistance argues against mutation theory of cancer
  
• Drug that battles resistance to leukemia pill Gleevec shown to be effective against cancer
  
• Drug Therapy Superior to Stem Cell Transplantation for CML
  
• Early BCR-ABL Kinase Inhibition Points to Leukemia Imatinib Response
  
• Early embryonic stem cell differentiation involves a protein kinase
  
• Early findings show promise as AS1411 AML study proceeds to higher-dose stage
  
• Early lymphocyte recovery predicts longer survival after stem cell transplantation
  
• Early multiple myeloma diagnosis and patient referral to oncologist recommended
  
• Early-onset thyrotoxicosis occurs after unrelated umbilical cord blood transplantation in acute myelogenous leukemia
  
• Easier to predict the future for leukemia patients
  
• EBV-associated gastric diffuse large B-cell lymphomas might be resistant to standard chemoradiotherapy
  
• EBV-associated gastric diffuse large B-cell lymphomas might be resistant to standard chemoradiotherapy
  
• EBV-associated gastric diffuse large B-cell lymphomas might be resistant to standard chemoradiotherapy
  
• Eculizumab Does Not Increase Risk of Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders: Presented at ASCO
  
• Effects of aging in stem cells
  
• Efficacy of shipped HLA-matched platelets is reported
  
• Elderly AML Patients Benefit More from Prolonged Post-Remission Therapy
  
• EMEA Grants Orphan Drug Designation To BioCryst's Fodosine(TM) For The Treatment Of Cutaneous T-Cell Lymphoma (CTCL)
  
• Emerging Therapies for CML (Video)
  
• Emory researchers identify signaling protein for multiple myeloma
  
• ENTREMED COMMENCES LEUKEMIA CLINICAL TRIAL FOR MKC-1 IN CANADA
  
• Enzon Pharmaceuticals initiates Oncaspar Phase I solid tumor trial
  
• EpiCept Accelerates Development of EPC2407 for Cancer
  
• EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
  
• EpiCept Receives Ceplene(R) Marketing Approval in Europe
  
• EpiCept Releases New Ceplene AML Data Demonstrating Leukemia Free Survival as Predictor of Improved Overall Survival
  
• EpiCept Reports Regulatory Progress on Ceplene(TM)
  
• ESAs cut survival by more than half in multiple myeloma
  
• European Commission Grants Orphan Drug Designation to Xanthus' Xanafide for the Treatment of Acute Myeloid Leukemia
  
• Every patient is unique: Individualized therapies for non-Hodgkin's lymphoma
  
• Exercise Rate Low in Childhood Leukemia Survivors
  
• Experimental Drug Shows Promise in Treating One Class of Lymphoma
  
• Experts Outline Use of Bisphosphonates Against Myeloma
  
• Exploring The Mechanisms Of Leukemia EHA Congress 2007
  
• Expression of CT45 in Hodgkin lymphoma is characterized
  
• Extracellular KIT receptor mutants, found in acute myelogenous leukemia (AML), respond to imatinib mesylate
  
• Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe
  
• FDA Approves Expanded Labeling for Campath to Include First-line Treatment for Leading Form of Adult Leukemia
  
• FDA Approves New Product to Treat Von Willebrand Disease
  
• FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
  
• FDA Approves Nilotinib for Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
  
• FDA Approves Vidaza Label Expansion
  
• FDA approves vorinostat (Zolinza) for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL)
  
• FDA Extends Review Of GENASENSE NDA Appeal in Chronic Lymphocytic Leukemia
  
• FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
  
• FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
  
• FDA Okays Sprycel for CML Resistant or Intolerant to Gleevec
  
• Fewer platelets could be used for some cancer and bone-marrow transplantation patients
  
• FHIT gene replacement therapy using a chimeric adenovirus shows promise for leukemia
  
• FHIT gene replacement therapy using a chimeric adenovirus shows promise for leukemia
  
• FHIT gene replacement therapy using a chimeric adenovirus shows promise for leukemia
  
• FHIT gene therapy using chimeric adenovirus shows promise for leukemia
  
• Fibroblast activation protein is a potential therapeutic target in myeloma
  
• Findings from Cell Signaling Technology, Inc. advance knowledge in acute myeloid leukemia genetics
  
• Findings from Children's Hospital in lymphoma in children reported
  
• Findings from Italy and Japan in leukemia provide new insights
  
• Findings from Peking Union Medical College, Medical College provide new insights into leukemia genetics
  
• Findings from the United States and United Kingdom describe new data in leukemia research
  
• Findings from University of Arizona, Arizona Cancer Center provide new insights into myelodysplastic syndrome
  
• Findings from University of Oslo, Biotechnology Center advance knowledge in waldenstrom macroglobulinemia
  
• FIREFLY GENES ALLOW TESTING OF NEW THERAPY AGAINST LYMPHOMA
  
• First antisense drug provides benefit to subset of chronic lymphocytic leukemia patients
  
• First Patient Undergoes Expanded Cord Blood Transplant in the ExCell Registration Study of StemEx(R) for Leukemia and Lymphoma
  
• Flow cytometry and quantitative PCR assesses minimal residual disease more accurately than consensus PCR in patients with chronic lymphocytic leukemia who underwent stem cell transplantation
  
• FLT3 D324N variant may be associated with a predisposition to different leukemia subtypes
  
• Fludara and Cytoxan Confirmed Standard Initial Treatment for CLL
  
• Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial
  
• Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin treatment is well tolerated in refractory and/or relapsed adult acute lymphoblastic leukemia
  
• Fludarabine-based regimen allows sustained engraftment without immediate toxicity
  
• Fludarabine-based regimen without irradiation is effective in patients with Fanconi anemia who are undergoing HLA-matched related donor hematopoietic cell transplantation
  
• Fms-like tyrosine kinase 3/ITD is a relevant marker for acute myeloid leukemia prognosis
  
• FoldRx Announces Its Phase II/III Clinical Study with Lead Clinical Candidate
  
• Forever young: Differentiation blocked in tumor stem cells
  
• Fostamatinib Disodium Effective for Diffuse B-Cell Lymphoma and CLL
  
• Four additional cancer centers join Multiple Myeloma Research Consortium
  
• Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study
  
• Fresh data on acute lymphoblastic leukemia are presented in the report "Cytogenetic patterns in ETV6/RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia
  
• Fresh data on B-cell lymphoma are presented in the report "DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma
  
• Fresh data on leukemia are presented in the report "Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2'-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB."
  
• Fresh data on lymphoma are presented in the report "Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas."
  
• Fresh data on lymphoma are presented in the report "Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition."
  
• Fresh data on stem cell research are presented in the report "Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus
  
• Full delivery of BEACOPP-14 chemotherapy for high-risk Hodgkin lymphoma enabled by pegfilgrastim support
  
• Function of molecular switch pinpointed in severe congenital neutropenia
  
• Further Data Shows R-CHOP Improves Survival in Elderly Patients with NHL
  
• G-CSF May Improve Outcomes of Patients with Severe Aplastic Anemia Treated with ATG and Cyclosporine
  
• Gemcitabine was used as a frontline treatment for cutaneous T-cell lymphoma (CTCL)
  
• Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
  
• Gemin X Pan Bcl-2 Inhibitor Obatoclax Demonstrates Biological and Clinical Activity in Heavily Pre-Treated Patients with Advanced Chronic Lymphocytic Leukemia
  
• Gene Abnormality Found to Predict Childhood Leukemia Relapse
  
• Gene expression molecular signature identified in chronic myeloid leukemia
  
• Gene expression profiling could be used to classify novel groups of acute myeloid leukemia (AML) and predict outcome
  
• Gene mutation improves leukemia drug's effect
  
• Gene Mutations Predict Treatment Outcomes in Patients With Leukemia
  
• Gene profiling can single out the worst cases of multiple myeloma and guide therapy
  
• Gene's Activity Points To More Lethal Subtype Of AML
  
• Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
  
• Genetics of imatinib resistance in acute lymphoblastic leukemia
  
• Genitope Corporation Reports Initial Results of Phase 3 Clinical Trial of MyVax(R) Personalized Immunotherapy
  
• Genmab A/S Regains Rights to HuMax-CD4
  
• Genmab Announces Early Results of Ongoing HuMax-CD4 Trials
  
• Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
  
• Genmab Initiates Ofatumumab Front Line NHL Study
  
• Genome changes tracked during multiple myeloma initiation, progression and treatment
  
• Genome Sequencer FLX System plus NimbleGen Sequence Capture Arrays Help Unravel the Cryptic Genetic Changes in Hematological Malignancies
  
• Genta Incorporated (NASDAQ: GNTA) today announced the publication of findings from a Phase 3 trial of the Company's lead anticancer drug, Genasense(R) (oblimersen sodium) Injection
  
• Genta to Request Review of FDA Action for Genasense NDA in Chronic Lymphocytic Leukemia
  
• Genta to Request Review of FDA Action for Genasense(R) NDA in Chronic Lymphocytic Leukemia
  
• Gentium’s Defibrotide Seen as Active in Multiple Myeloma
  
• Genzyme Begins Phase 2 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
  
• Genzyme Corporation (GENZ) announced the availability of a new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate)
  
• Genzyme to initiate tender offer to acquire AnorMED, Inc.
  
• Geron Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
  
• GlaxoSmithKline (GSK) and Genmab, A/S, announced a worldwide agreement to codevelop and commercialize HuMax-CD20 (ofatumumab)
  
• GlaxoSmithKline And Genmab Announce Positive Top-line Results In Ofatumumab Chronic Lymphocytic Leukaemia Pivotal Study
  
• GlaxoSmithKline plc (GSK) announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) seeking marketing approval for ATRIANCE (nelarabine)
  
• GlaxoSmithKline's Atriance (nelarabine) Receives Positive Opinion In Europe For The Treatment Of Rare, Difficult To Treat Leukaemias And Lymphoma
  
• Gleevec, the wildly successful poster-child of a new generation of cancer drugs aimed at specific targets in the cancer cell, can be dangerous to the heart
  
• Glioma-produced extracellular matrix influences brain tumor tropism of neural stem cells
  
• Gloucester Pharmaceuticals Announces Phase 2 Data for Romidepsin Showing Durable Response in Refractory CTCL
  
• Gloucester Presents Positive Results From Phase IIb Lymphoma Trial
  
• Glucocorticoid (GC) resistance in acute lymphoblastic leukemia (ALL) was not due to an inability of resistant cells to up-regulate the expression of the glucocorticoid receptor (GR)
  
• Graft-versus-host disease is a major determinant of the long-term quality of life of survivors following hematopoietic stem cell transplantation
  
• Graft-Versus-Host Disease: A Surge of Developments
  
• Graft-versus-leukemia effect is demonstrated in patients with chronic myelomonocytic leukemia who undergo allogeneic stem cell transplantation or donor lymphocyte infusion
  
• Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds
  
• Green Tea May Negate the Benefits of Velcade
  
• GSK to Launch Inexpensive Orphan Leukemia Drug Atriance in Europe
  
• GTx Initiates Phase IIb Ostarine Clinical Trial for Cancer Cachexia
  
• Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome
  
• Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
  
• Hana Biosciences' Marqibo Receives Orphan Designation From European Commission for the Treatment of Adult Acute Lymphoblastic Leukemia
  
• Hana Biosciences' rALLy Clinical Trial of Marqibo Meets Response Criteria to Advance to Full Enrollment
  
• Hard-to-Treat Leukemia Cell Subtype Identified
  
• Head and neck amyloidosis reviewed in clinicopathologic study of 15 cases
  
• Health Canada approves bortezomib for second-line use in multiple myeloma patients
  
• Heat therapy for cancer may be key to testicular cancer survival rates
  
• Heller Institute of Medical Research details research in amyloidosis immunology
  
• Hemochromatosis (HFE) gene mutations are not risk factors for developing leukemia in Mexican mestizos
  
• Hereditary systemic amyloidosis amyloidogenic transthyretin can be selectively suppressed
  
• High Unmet Need Creates Opportunity for Novel Non-Hodgkin's Lymphoma Drugs in Europe
  
• High-dose chemotherapy and stem cell transplant feasible in myeloma and AL amyloidosis
  
• High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
  
• High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
  
• High-dose Methotrexate Provides Long-term Results in Central Nervous System Lymphoma
  
• Highly diverged MHC class I mismatches are acceptable for haematopoietic stem cell transplantation
  
• HLA-A*0201-presented epitopes from oncofetal laminin receptor protein have been identified
  
• Hodgkin lymphoma -- new characteristics discovered
  
• Hodgkin lymphoma cellular composition influenced by interleukin-9 expression
  
• Hodgkin lymphoma involves high expression of activating transcription factor 3
  
• Hodgkin lymphoma pathogenesis linked to inflammation caused by Epstein-Barr virus
  
• Hodgkin lymphoma patients did not benefit more from radiotherapy than consolidation chemotherapy
  
• Hodgkin lymphoma patients did not benefit more from radiotherapy than consolidation chemotherapy
  
• Hodgkin lymphoma patients with bulky lymph nodes estimated by power Doppler ultrasound scanning
  
• Hodgkin lymphoma prevented by alcohol drinking
  
• Hodgkin lymphoma residual disease and relapse detected by FDG-PET
  
• Hodgkin lymphoma response monitoring by FDG-PET explained
  
• Hodgkin lymphoma treatment with BEACOPP proposed as new standard
  
• Hodgkin's lymphoma survivors show higher risk of second cancers
  
• Hodgkin-Reed-Sternberg cells inhibit apoptosis via caspase-3 interference
  
• How molecules out of balance lead to human multiple myeloma and other cancers
  
• HOX-induced acute myeloid leukemia treated by specific Flt3 inhibitors
  
• HoxA proteins are a problem for acute myeloid leukemia
  
• HSV-1 amplicon viral vector-mediated gene transfer to human bone marrow-derived mesenchymal stem cells
  
• Human C-reactive protein regulates myeloma tumor cell growth and survival
  
• Human leukemic cells were killed by nuclear entrapment of BCR-ABL
  
• Human T cell leukemia virus type 1-induced cellular transformation linked to TAX
  
• Human T-cell leukemia virus type 1 and HTLV-2 use different receptor complexes to enter T cells
  
• HuMax-CD38 shows unique property in preclinical studies
  
• Hyperglycemia Linked to Hospital Mortality in AML Patients
  
• Hypoxia induces 4-HPR resistance in leukemia cells
  
• Idiotype-specific immunotherapy in multiple myeloma is focus of review
  
• IL-7R alpha polymorphisms related to treatment-related mortality after SCT
  
• Imatinib and Steroids Helpful in Elderly with Acute Lymphoblastic Leukemia
  
• Imatinib mesylate enhances chronic myeloid leukemia stem cell elimination
  
• Imatinib mesylate treats secondary malignancy with favorable outcome
  
• Imatinib-resistant Philadelphia chromosome-positive (Ph-positive) leukemias could be treated using dasatinib
  
• Immunoglobulin (Ig) mutational status could be used as a prognostic marker for clinical outcome in chronic lymphocytic leukemia (CLL)
  
• Immunomedics Awarded U.S. Patent for Internalizing Anti-CD74 Antibodies and Methods of Use
  
• Immunomedics Reports Veltuzumab Enhances Radioimmunotherapy With Epratuzumab in Lymphoma Model
  
• Immunomedics says lymphoma drug is promising in preclinical studies
  
• Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
  
• Immunomedics, Inc. (IMMU)'s Milatuzumab receives FDA orphan drug designation
  
• Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
  
• In multiple myeloma patients, different gamma/delta T clones sustain GVM and GVH effects after non-myeloablative transplantation
  
• Incidence of bacteremias and invasive mycoses in children undergoing allogeneic hematopoietic stem cell transplantation: a single center experience
  
• Incidence of leukemia and testicular cancer heightened in persons with Down syndrome in Finland
  
• Incidence of leukemia, lymphoma, and multiple myeloma in Czech uranium miners studied
  
• Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer
  
• Increased use of Mylotarg and new drugs more than doubles the market for AML therapies
  
• Individuals with Down syndrome have higher leukemia risk but lower solid tumor risk
  
• Induction therapy with high-dose cytosine arabinoside (HDAraC) improved disease control and survival in acute myeloid leukemia (AML) patients age <60 years; its effects on prognostically different leukemia subgroups need further study
  
• Induction therapy with high-dose cytosine arabinoside (HDAraC) improved disease control and survival in acute myeloid leukemia (AML) patients age > 60 years; its effects on prognostically different leukemia subgroups need further study
  
• Infant leukemia linked to MLL fusion genes
  
• Infants with acute lymphoblastic leukemia (ALL) and a germline MLL gene could be cured by the chemotherapy regimen described herein
  
• Infants with acute lymphoblastic leukemia (ALL) and a germline MLL gene could be cured by the chemotherapy regimen described herein
  
• Infections documented among children undergoing allogeneic BMT in India
  
• Inhibiting p38 MAPK signaling restores dendritic cell function in multiple myeloma
  
• Inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma
  
• Inhibitory anti-FGFR3 antibody is cytotoxic to t(4;14) multiple myeloma cells
  
• Initial Patients Treated in Multinational Phase 2/3 Study of Ceflatonin
  
• Initial response of leukemia to chemotherapy could predict event-free survival
  
• Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
  
• Injection strength Velcade shown effective against hematological cancers
  
• InNexus Biotechnology unveils new platform for augmenting antibody therapeutics
  
• Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
  
• INNOVIVE Pharmaceuticals Initiates Pivotal Phase II Clinical Trial with Tamibarotene
  
• INNOVIVE Pharmaceuticals Presents Additional Phase I Data on INNO-406 for Treatment of Gleevec-Resistant or Intolerant Chronic Myelogenous Leukemia at the American Society of Clinical Oncology Annual Meeting
  
• INNOVIVE Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for Pivotal Phase II Clinical Trial with Tamibarotene in Refractory Acute Promyelocytic Leukemia
  
• INNOVIVE Pharmaceuticals Receives FDA Fast Track Designation for Tamibarotene for the Treatment of Acute Promyelocytic Leukemia
  
• Intercampus initiative works to increase participation in clinical trials; first phase of study to focus on cancer
  
• Interferon-alpha therapy has activity in children with advanced Hodgkin lymphoma
  
• Interferon-alpha therapy has activity in children with advanced Hodgkin lymphoma
  
• Interim analysis of anti-cancer vaccine, BiovaxID, to be conducted
  
• Intrabone admin of unrelated cord-blood cells lets more leukemia patients undergo transplantation
  
• Inverted DNA turns quiet developmental gene into a potent driver of t-cell lymphoma
  
• Investigators addressed HRQOL concerns over use of dexamethasone in children with acute lymphoblastic leukemia (ALL)
  
• Investigators at Kyoto Prefectural University, Department of Medicine have published new data on myeloma therapy
  
• Investigators at Peking Union Medical College, Medical College release new data on acute lymphoblastic leukemia risk factors
  
• Investigators at Shinshu University, Department of Laboratory Medicine target acute myelogenous leukemia
  
• Investigators at Taipei Medical University, Department of Internal Medicine zero in on leukemia cell biology
  
• Investigators at University Hospital zero in on follicular lymphoma therapy
  
• Investigators at University of Kansas release new data on t-cell leukemia
  
• Investigators at University of Texas, M.D. Anderson Cancer Center have published new data on chronic lymphocytic leukemia therapy
  
• Investigators have used allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia
  
• Investigators have used allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia
  
• Investigators have used allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia
  
• Investigators present prospects for immune therapy of acute myeloid leukemia in a recent issue of Cancer Immunology Immunotherapy
  
• Investigators present prospects for immune therapy of acute myeloid leukemia in a recent issue of Cancer Immunology Immunotherapy
  
• Investigators review the antigen-specific cellular immunotherapy of leukemia in a recent issue of the journal Leukemia
  
• Investigators review the antigen-specific cellular immunotherapy of leukemia in a recent issue of the journal Leukemia
  
• Itraconazole and caspofungin both provided antifungal prophylaxis in patients with hematologic malignancies
  
• Itraconazole and caspofungin both provided antifungal prophylaxis in patients with hematologic malignancies
  
• Janus kinase (Jak) 2 was identified as a potential therapeutic target in chronic myelogenous leukemia (CML)
  
• Journal of Clinical Oncology Publishes Data on ZOLINZA™ (vorinostat), Merck's Treatment for Advanced Cutaneous T-cell Lymphoma
  
• Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma
  
• Juvaris wins innovation research grant for acute myelogenous leukemia vaccine development
  
• Karyotypes of patients with adult acute myeloid leukemia (AML) were analyzed in a demographic study
  
• Keryx Biopharmaceuticals (KERX) Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
  
• Kidney Cancer Drug Attacks a Major Type of Acute Myeloid Leukemia
  
• KNOCKING OUT SURVIVAL PROTEIN COULD AID LEUKEMIA TREATMENT
  
• Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
  
• Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
  
• Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows Antitumor Activity in Multiple Myeloma
  
• Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA(TM)) Treatment for Patients with Amyloid A (AA) Amyloidosis
  
• Lenalidomide (REVLIMID(R)) Receives Orphan Medicinal Product Designation from the European Commission for Chronic Lymphocytic Leukemia
  
• Lenalidomide offers new hope for patients with chronic lymphocytic leukemia
  
• Lenalidomide raises clot risk in multiple myeloma patients
  
• Leukemia & Lymphoma Society launches back-to-school program for children with cancer
  
• Leukemia and lymphoma immunophenotypes are determined from an antibody microarray
  
• Leukemia and other hematological cancers advance when tissue factor stimulates angiogenesis
  
• Leukemia antiproliferation and apoptosis induced by C-glycosides
  
• Leukemia apoptosis induced by cisplatin
  
• Leukemia apoptosis induced by dehydroxymethylepoxyquinomicin
  
• Leukemia apoptosis sensitivity decreased by Fas phosphorylation
  
• Leukemia bears N-terminally truncated protein with oncogenic properties
  
• Leukemia bears N-terminally truncated protein with oncogenic properties
  
• Leukemia bears N-terminally truncated protein with oncogenic properties
  
• Leukemia cell stimulation of bone marrow angiogenesis encourages cancer progression
  
• Leukemia cell stimulation of bone marrow angiogenesis encourages cancer progression
  
• Leukemia cell stimulation of bone marrow angiogenesis encourages cancer progression
  
• Leukemia could be treated by tetrandrine (TET) combined with daunorubicin (DNR), etoposide and cytarabine (TET-DEC)
  
• Leukemia developed in patient with primary thrombocythemia and absence of BCR/ABL rearrangement
  
• Leukemia drug proves safe and effective over the long term
  
• Leukemia drug turns mini-molecules up, cancer genes down
  
• Leukemia drug turns mini-molecules up, cancer genes down
  
• Leukemia in infants prognosticated by MLL/11q23 rearrangement, CD10 expression, and age
  
• Leukemia inhibition of retinoic acid receptor signaling by Ski evaluated in acute myeloid leukemia
  
• Leukemia inhibition of retinoic acid receptor signaling by Ski was evaluated in acute myeloid leukemia (AML)
  
• Leukemia inhibitory factor (LIF) regulation of cardiac stem cells may support neovascularization
  
• Leukemia inhibitory factor stimulates glucose transport in isolated cardiomyocytes and induces insulin resistance after chronic exposure
  
• Leukemia linked to gain-of-function mutations of nucleophosmin
  
• Leukemia might be linked to CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes
  
• Leukemia p53-mediated apoptosis induced by Mdm2 inhibitor Nutlin-3a
  
• Leukemia pathogenesis linked to c-Abl overexpression
  
• Leukemia patients experienced molecular remission after imatinib treatment
  
• Leukemia patients find new hope in adaphostin therapy
  
• Leukemia patients identified with seemingly normal circulating dendritic cell compartment
  
• Leukemia patients may find new hope in novel valproic acid (VPA) derivatives with potent differentiation-inducing and anti-proliferative properties
  
• Leukemia patients may find new hope in novel valproic acid (VPA) derivatives with potent differentiation-inducing and anti-proliferative properties
  
• Leukemia patients receiving imatinib should be advised to practice adequate contraception
  
• Leukemia patients were recommended daily dose of 5 mg/m2day of semisynthetic homoharringtonine
  
• Leukemia patients' illness perception, lay theories, and coping strategies analyzed
  
• Leukemia patients' loss of tumor protein 53 resulted from absence of chromosome 17 p-arm
  
• Leukemia progression could be inhibited by virgin olive oil phenols
  
• Leukemia Research has chronicled a phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with AML receiving high-dose cytarabine during induction
  
• Leukemia response to chemotherapy predicted by CASP8AP2 expression
  
• Leukemia response to dasatinib evaluated
  
• Leukemia response to topoisomerase II poisons reduced when treated with digitoxin concurrently
  
• Leukemia risk heightened due to high magnetic field exposure
  
• Leukemia survival and time to initiation of therapy could be predicted by CLLU1 expression
  
• Leukemia survival was not linked to NRAS mutations [NRAS(mut)]
  
• Leukemia Therapy With Imatinib During Pregnancy May Cause Infant Abnormalities
  
• Leukemia treated by 131I-anti-CD45 antibody plus busulfan and cyclophosphamide
  
• Leukemia treated by cyclophosphamide plus mitoxantrone more effectively than cladribine
  
• Leukemia treated with bortezomib experienced enhanced cytotoxic effects of combination chemotherapy
  
• Leukemia, refractory to imatinib mesylate, treated with AMN107 and LBH589
  
• Leukemia-associated gain-of-function mutation affects interleukin-3 signaling
  
• Leukemias caused by BCR/ABL find new hope in novel therapies that target Rap1
  
• Leukemic cell photodynamic destruction is activated by chemiluminescence
  
• Leukemic oncogenes identified by phosphoproteomic analysis
  
• Leukemic transformation during fetal hematopoiesis might be promoted by constitutional trisomy 21
  
• Link between leukemia prognosis and multidrug resistance-related proteins studied
  
• Lonafarnib could be used to treat select patients with chronic myelogenous leukemia (CML) refractory to imatinib
  
• Lonafarnib May Enhance Effect of Imatinib in Refractory Leukemia
  
• Long-term donor health associated with recipient stem cell transplantation outcome
  
• Long-term outcome results of the first tandem autotransplant trial for multiple myeloma are assessed
  
• LORUS ADVANCES CLINICAL DEVELOPMENT OF GTI-2040 COMBINED WITH ARA-C IN ACUTE MYELOID LEUKEMIA
  
• Lorus Therapeutics announces presentation on GTI-2040 uptake by tumor cells in acute myeloid leukemia
  
• Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia
  
• Lorus Therapeutics announces the initiation of a clinical trial of GTI-2040 in acute leukemia and myelodysplastic syndrome
  
• Loss of Immune Control of Epstein-Barr Virus Tied to Lymphoma Risk
  
• Low micro-RNA level linked to high gene activity in AML
  
• Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment
  
• Low-grade lymphoma progression to high-grade disease observed by FDG-PET
  
• Lung cancer screened for in Hodgkin lymphoma survivors by computed tomography
  
• Lymphoblastic leukemias could be linked to aberrant stabilization of c-Myc protein
  
• Lymphocyte count found to be a predictor of survival for young patients with leukemia
  
• Lymphocyte count found to be a predictor of survival for young patients with leukemia
  
• Lymphoma 101: Everything you need to know
  
• Lymphoma and leukemia diagnosed by endoscopic ultrasound-guided fine-needle aspiration biopsy
  
• Lymphoma apoptosis was induced by down-regulating constitutive activation of the nuclear factor-kappa B (NF-kappa B) canonical pathway
  
• Lymphoma Causes Are Now Better Understood
  
• Lymphoma cells: Hedging against apoptosis
  
• Lymphoma could be evaluated postoperatively by the value of fluorine-18-fluorodeoxyglucose (FDG) triple-head coincidence PET
  
• Lymphoma could be treated by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy, warranting a larger scale study
  
• Lymphoma Drug Used to Treat Skin Disorders
  
• Lymphoma evaluated postoperatively by value of FDG triple-head coincidence PET
  
• Lymphoma foundation launches educational initiative targeting multicultural populations
  
• Lymphoma pathogenesis could be associated with FLICE-like inhibitory protein (c-FLIP) overexpression
  
• Lymphoma response to methotrexate might be affected by reduced folate carrier 1 (RFC1) genetic polymorphisms
  
• Lymphoma response to methotrexate might be affected by reduced folate carrier 1 polymorphisms
  
• Lymphoma survival could be predicted by integrated clinical and gene expression information
  
• MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
  
• Maintenance rituximab useful for advanced indolent lymphoma
  
• Major gene study uncovers secrets of leukemia
  
• Major Phase 3 Trial Shows Zevalin Extends Progression-free Survival in One of the Most Common Types of Lymphoma
  
• Male Infertility Linked to Testicular Cancer
  
• Malignancies and infections are important causes of late nonrelapse mortality after stem cell transplantation
  
• Malignancies and infections cause late nonrelapse mortality after stem cell transplantation
  
• Malignant lymphoma was associated with chromosome band 6q deletion pattern
  
• MALT lymphoma-associated translocations were not linked to nuclear B-cell lymphoma 10 (BCL-10) expression
  
• Mantle cell lymphoma (MCL) could be prognosticated with the Follicular Lymphoma International Prognostic Index (FLIPI)
  
• Mantle cell lymphoma (MCL) pathogenesis and survival could be linked to constitutive activation of PI3K/Akt
  
• Marrow from acute myeloid leukemia (AML) patients produces extra angiopoietin
  
• Mayo Clinic Cancer Center -- Investigating the Measles Virus as a Tool to Kill Multiple Myeloma
  
• Mayo Clinic Researchers Find Predictive Tests and Early Treatment Delay Progression of Blood Cell Cancer
  
• Med BioGene Confirms High Accuracy Rate for LymphExpress Dx
  
• Med BioGene Welcomes Renowned Expert to Lymphoma Collaboration
  
• Medical College of Wisconsin study finds drug may limit radiation kidney damage in BMT patients
  
• Memgen's Clinical Results on Leukemia Selected for Presentation at 2008 ASH Annual Meeting
  
• Merck and Vertex Announce Phase I Results for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680); Compound Showed Activity in Patients with Treatment-Resistant Forms of Advanced Leukemias and Myeloproliferative Disorders
  
• Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) in Patients with Treatment-Resistant Forms of Advanced Leukemias
  
• MethylGene Initiates Single-Agent Phase II Clinical Trial With its HDAC Inhibitor, MGCD0103, in Patients With Refractory Chronic Lymphocytic Leukemia
  
• MethylGene Initiates Single-Agent Phase II Clinical Trial With its HDAC Inhibitor, MGCD0103, in Patients With Refractory Chronic Lymphocytic Leukemia
  
• MGI Pharma, INC. (MOGN), a biopharmaceutical company focused in oncology and acute care, provided a summary of the Dacogen (decitabine) for Injection
  
• Microenvironment a main driver of aggressive multi-lineage leukemia disease type
  
• Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients
  
• Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
  
• Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma
  
• MicroRNA works with Ago2 protein to regulate blood cell development
  
• Mile High Amazing Race Downtown Denver 5/17
  
• Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
  
• Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients
  
• Millennium Pharmaceuticals, Inc. (MLNM) announced results from additional studies of Velcade in a variety of cancers, including multiple myeloma, non-Hodgkin lymphoma and non-small cell lung cancer
  
• Millennium Pharmaceuticals, Inc. (MLNM) announced results of a clinical study that showed the efficacy of single-agent Velcade in the treatment of relapsed or refractory mantle cell lymphoma (MCL)
  
• Millennium Pharmaceuticals, Inc. (MLNM) announced the publication of clinical data of Velcade in the treatment of newly diagnosed multiple myeloma (MM), MM accompanied by advanced renal failure, and mantle cell lymphoma (MCL)
  
• Minimal residual disease (MRD) measurement could prognosticate childhood acute lymphoblastic leukemia (ALL) outcomes
  
• MMRF, MMRC Launch Multiple Myeloma Genomics Portal
  
• Molecular change may reveal risk of leukemia relapse
  
• Molecular detectors may refine cancer treatment
  
• Molecular science could further improve leukemia survival say St Jude researchers
  
• MolecularMD Joins CML ALLIANCE(TM) to Provide Standardized qRT-PCR BCR-ABL Patient Monitoring Diagnostics
  
• MolecularMD signs agreement to support phase 2 trial of vaccine in chronic myeloid leukemia
  
• Molecules might identify high-risk acute-leukemia patients
  
• Monocytic leukemia zinc-finger protein is essential for the maintenance of hematopoietic stem cells
  
• Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients
  
• Mouse model highlights histone methylation as distinguishing feature for leukemia subtypes
  
• Multiple myeloma (MM) is linked to differential vascular endothelial growth factor (VEGF) expression
  
• Multiple myeloma (MM) patients could be at risk for developing osteonecrosis of the jaw (ONJ)
  
• Multiple myeloma cell growth is predominantly stimulated by bone-derived insulin-like growth factors
  
• Multiple myeloma cell growth predominantly stimulated by bone-derived IGFs
  
• Multiple myeloma chemoresistance may be overcome by bortezomib
  
• Multiple myeloma clinical trial closes early
  
• Multiple myeloma could be treated by the histone deacetylase inhibitor LBH589
  
• Multiple myeloma could be treated by the histone deacetylase inhibitor LBH589
  
• Multiple myeloma of the cervical spine palliated by external-beam radiation
  
• Multiple myeloma outcome after standard chemotherapy was comparable to high-dose chemoradiotherapy
  
• Multiple myeloma patients associated with risk of osteonecrosis of the jaw
  
• Multiple Myeloma Research Consortium (MMRC), Emory University Commence Multi-Center Combination Study for the Treatment of Multiple Myeloma
  
• Multiple Myeloma Research Consortium launches myeloma genome mapping program
  
• Multiple Myeloma Research Consortium Partners with Novartis Pharmaceuticals Corporation (NVS) to Advance Phase II Study of Deacetylase Inhibitor
  
• Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) Announce Strategic New Hires
  
• Multiple Myeloma Research Foundation's (MMRF) Annual Gala Raises More Than $1.5 Million to Advance Cancer Research
  
• Multiple myeloma treatment by osteoblast suppression described
  
• Multiple myeloma treatment results interpreted by patient-reported outcomes
  
• Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?
  
• Multiple myeloma-derived circulating endothelial cells may foster tumor vessel growth
  
• Multiple myelomas acquired resistance to activated protein C increased venous thromboembolism risk
  
• Multiple myelomas malignant transformation linked to increase of functional regulatory T cells
  
• Multiple myelomas strong link to personal/familial autoimmune disorders not supported
  
• Murine models of human juvenile myelomonocytic leukemia (JMML) are used to explore novel therapies
  
• Mutant nucleophosmin (NPM1) could be used to predict favorable prognosis in younger adults with acute myeloid leukemia (AML)
  
• Mutant nucleophosmin (NPM1) could be used to predict favorable prognosis in younger adults with acute myeloid leukemia (AML)
  
• Myelodysplastic syndrome not treated by thalidomide therapy at current dose schedule
  
• Myelogenous leukemia relapse may occur due to possible alternation between leukemia stem cell cycling and quiescence modes
  
• Myelogenous leukemia relapse may occur due to possible alternation between leukemia stem cell cycling and quiescence modes
  
• Myelogenous leukemia relapse may occur due to possible alternation between leukemia stem cell cycling and quiescence modes
  
• Myelogenous leukemia relapse may occur due to possible alternation between leukemia stem cell cycling and quiescence modes
  
• Myeloid hematopoietic stem cells with minimal lymphopoietic potential may be the acute myeloid leukemia transformation site
  
• Myeloid leukemia cell line with MLL-ENL fusion gene established
  
• Myeloma cell apoptosis and cell cycle inhibition are induced by mycophenolate mofetil
  
• Myeloma cell apoptosis and cell cycle inhibition are induced by mycophenolate mofetil
  
• Myeloma characterized by chromosomal aberrations
  
• Myeloma screening with turbidimetric immunoassays has limited value
  
• Myeloma thalidomide and/or stem cell autotransplant treatment improves survival
  
• Myeloma treated by histone deacetylase inhibitor LBH589
  
• Myeloma was characterized by chromosomal aberrations via interphase fluorescence in situ hybridization, resulting in data of prognostic value
  
• Myeloma was characterized by chromosomal aberrations via interphase fluorescence in situ hybridization, resulting in data of prognostic value
  
• Myelomas suppressed by CD32 expression
  
• Natriuretic peptides reflect the transient cardiac effect following high-dose cyclophosphamide in patients with non-Hodgkin's lymphoma
  
• Natriuretic peptides reflect the transient cardiac effect following high-dose cyclophosphamide in patients with non-Hodgkin's lymphoma
  
• Negative outcome in acute myeloid leukemia (AML) could be associated with c-KIT mutations
  
• Negative outcome in acute myeloid leukemia (AML) could be associated with c-KIT mutations
  
• Nelarabine effective for some leukemia and lymphoma patients
  
• Nerve cancer mutations found
  
• Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
  
• Neurochem receives approvable letter for eprodisate for treatment of amyloidosis
  
• Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
  
• Neuropathy Common in Multiple Myeloma Patients Treated with Thalidomide
  
• New acute lymphoblastic leukemia in children study findings have been reported by scientists at University of Alberta
  
• New agents for management of myelodysplastic syndromes are focus of review
  
• New b-cell lymphoma research reported from University of Texas, M.D. Anderson Cancer Center
  
• New cancer research from Fred Hutchinson Cancer Research Center described
  
• New chronic myelogenous leukemia therapy data have been reported by scientists at University of Texas, M. D. Anderson Cancer Center
  
• New data from Centre for Study and Prevention of Cancer illuminate research in myeloma prevention
  
• New drug combination brings 1-2 punch against acute leukemia
  
• New drug target might sidestep Gleevec resistance
  
• New Drug Therapy to Combat Graft-vs.-Host Disease in Stem-Cell Patients Shows Significant Reduction in Deaths
  
• New Findings About Dangerous Cancer Protein
  
• New findings from Erciyes University, Department of Pediatric Hematology in the area of acute myeloid leukemia in children published
  
• New findings from Stanford University in the area of acute myeloid leukemia described
  
• New findings from University of Perugia, Institute of Hematology in the area of acute myeloid leukemia published
  
• New findings reported from University of Rome describe advances in leukemia
  
• New genes involved in acute lymphoblastic leukemia play fundamental role in prognosis of the disease
  
• New Genes Linked to Testicular Cancer
  
• New Insight on Survival for Patients with Head and Neck Cancers After Lymphoma
  
• New investigation results, "Clonal evolution of lymphoblastoid cell lines," are detailed in a study published in Laboratory Investigation
  
• New investigation results, "Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure," are detailed in a study published in Blood
  
• New investigation results, "Induction of remission of relapsed acute myeloid leukemia after unrelated donor cord blood transplantation by concomitant low-dose cytarabine and calcitriol in adults," are detailed in a study published in European Jo
  
• New investigation results, "Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants," are detailed in a study published in Supportive Care In Cancer
  
• New investigation results, "Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants," are detailed in a study published in Supportive Care In Cancer
  
• New investigation results, "Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk MDS
  
• New investigation results, "Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}," are detailed in a study published in Journal of
  
• New investigation results, "STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells
  
• New investigation results, "Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181," are detailed in a study published in Cancer Research
  
• New investigation results, "Umbilical cord blood transplantation and cytomegalovirus: Posttransplantation infection and donor screening," are detailed in a study published in Blood
  
• New Label Recommends Lower Starting Dose for BMS Cancer Drug
  
• New leukemia prevention research reported from Centers for Disease Control and Prevention
  
• New leukemia risk factors research from Sun Yat-Sen University outlined
  
• New leukemia signal could point way to better treatment, Stanford researchers find
  
• New leukemia therapies bring promise of cure
  
• New leukemia therapy data have been reported by researchers at Medical University of Lodz, Faculty of Pharmacy
  
• New leukemia therapy study findings have been reported by investigators at Tohoku Pharmaceutical University, Cancer Research Institute
  
• New lymphoma therapies targets diverse and difficult cancer
  
• New lymphoma therapy research from University of Arizona, Arizona Cancer Center described
  
• New myeloma epidemiology data have been reported by scientists at University of Southern California, Department of Preventive Medicine
  
• New myeloma therapy findings from Kyoto Prefectural University, Department of Hematology described
  
• New research on myelocytic leukemia immunology from Seoul National University, Department of Pathology summarized
  
• New research provides hope for childhood cancer sufferers
  
• New research, "CT diagnosis of 52 patients with lymphoma in abdominal lymph nodes," is the subject of a report
  
• New research, "Sacroiliitis as an initial manifestation of acute myelogenous leukemia," is the subject of a report
  
• New research, "Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)," is the subject of a report. "Second mitochondria-derived activator of caspases (Smac) promotes apoptosis via activation of caspases
  
• New Risk Model for MDS Applies to All Stages of Disease
  
• New Study by ARIAD Scientists Offers Insights into Design of Small-Molecule Drugs to Treat Drug-Resistant Leukemia
  
• New Study Offers Hope For Patients With Advanced Follicular Lymphoma
  
• New t-cell leukemia data have been reported by researchers at University of Massachusetts, Department of Cancer Biology
  
• New testicular cancer therapy research has been reported by scientists at King's College London, King's College London
  
• New therapies are being developed that bring the promise of a cure for leukemia
  
• New treatment approach promising for lymphoma patients in the developing world
  
• New treatments fight GVHD in bone marrow transplant patients
  
• New weapon to fight leukemia
  
• Nicholas Piramal India Limited's IND P276 a new drug discovery from Mumbai, India has been approved by USFDA
  
• Nilotinib a Second-Line Treatment for Chronic Myelogenous Leukaemia: Presented at NCCN
  
• No complete remissions observed in study of alemtuzumab for leukemia patients
  
• Non-Hodgkin lymphoma (NHL) could be treated with less intensive therapy
  
• Non-Hodgkin lymphoma (NHL) survivors had an increased risk of developing secondary malignancies; the risk varied according to age at NHL diagnosis, gender, and treatment
  
• Non-Hodgkin lymphoma (NHL) survivors had an increased risk of developing secondary malignancies; the risk varied according to age at NHL diagnosis, gender, and treatment
  
• Non-Hodgkin lymphoma patients responded to high-dose carmustine, etoposide, and cyclophosphamide
  
• Non-Hodgkin lymphoma risk linked to genetic variation in N-acetyltransferase 1 and 2
  
• Non-Hodgkin lymphoma risk might be affected by diet
  
• Non-Hodgkin Lymphoma Survivors at Risk for New Cancers, Early Death
  
• Normal karyotype acute myeloid leukemia (AML) could be prognosticated by breast cancer resistance protein (BCRP)
  
• Novacea Announces Positive AQ4N Phase 1 Study in Lymphoma at ASH Annual Meeting
  
• Novacea Initiates Phase 2 Trial of AQ4N in Acute Lymphoblastic Leukemia
  
• Novel strategy under study for aggressive leukemia
  
• NS-187 was proposed as a novel agent for imatinib-resistant leukemia
  
• Obese children with leukemia have poorer outlook
  
• Obesity Found to be a Risk Factor for Multiple Myeloma
  
• Ofatumumab Promising in Refractory Follicular Lymphoma
  
• OHSU Cancer Institute Researchers Help Develops Test For Targeted Therapy In Acute Myeloid Leukemia
  
• OHSU Cancer Institute researchers identify new approach to help control drug resistance in leukemia
  
• Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
  
• ONTAK(R) (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
  
• ORLive Presents: New Developments in Lymphoma Treatments Live Interactive Panel Discussion
  
• OSI Pharmaceuticals Begins Clinical Development Program for OSI-027 in Patients with Advanced Solid Tumors or Lymphoma
  
• Osteoclast-like transformation of cultured human myeloma cell lines depends on RANK-L stimulation
  
• Outcome of pediatric acute myeloid leukemia (AML) was not improved after high-dose daunorubicin, cytarabine, and thioguanine (DAT) therapy and the addition of cyclosporine (CsA)
  
• Outcome of pediatric acute myeloid leukemia (AML) was not improved after high-dose daunorubicin, cytarabine, and thioguanine (DAT) therapy and the addition of cyclosporine (CsA)
  
• Outlook for multiple myeloma improves due to new therapies
  
• Outlook improves for patients with non-Hodgkin lymphoma over past decade
  
• Panacea Pharmaceuticals' test predicts response to therapy in chronic myelogenous leukemia
  
• Parental and infant characteristics and childhood leukemia in Minnesota
  
• Patient Becomes Unlikely Inventor Of Leukemia-Fighting Technology
  
• Patients can have monoclonal gammopathies and hereditary amyloid proteins
  
• Patients in the blast crisis (BC) stage of chronic myelogenous leukemia (CML) might be treated by restoring C/EBP activity
  
• Patients in the blast crisis (BC) stage of chronic myelogenous leukemia (CML) might be treated by restoring C/EBP activity
  
• Patients in the blast crisis (BC) stage of chronic myelogenous leukemia (CML) might be treated by restoring C/EBP activity
  
• Patients with chronic myelogenous leukemia or gastrointestinal stromal tumors receiving imatinib mesylate exhibited altered bone and mineral metabolism
  
• Patients with de novo acute myeloid leukemia (AML) experienced high complete remission (CR) rates after their first induction therapy with homoharringtonine in combination with cytarabine and aclarubicin (HAA)
  
• Patients with Lymphoma and CLL Are at Increased Risk of Lung Cancer
  
• Patients with treatment-resistant leukemia achieve high responses to Tasigna (nilotinib) in first published clinical trial results
  
• Pediatric acute lymphocytic leukemia characterized
  
• Pediatric stem cell transplantation program established in Chile
  
• Pediatric T-cell acute lymphoblastic leukemia (ALL) could be linked to ectopic expression of the proto-oncogene Mer
  
• Pediatric T-cell acute lymphoblastic leukemia (ALL) could be linked to ectopic expression of the proto-oncogene Mer
  
• Pegfilgrastim mobilizes peripheral blood stem cells in poor mobilizer multiple myeloma
  
• Perifosine inhibits Akt and induces cytotoxicity in human multiple myeloma cells
  
• Peripheral blood stem cell transplantation is well tolerated and feasible in patients aged 60 and older with acute myelogenous leukemia and in first complete remission
  
• PET/CT could be used to detect Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large cell lymphoma with a high sensitivity and a high negative predictive value
  
• Pharmacogenomic study findings could aid decision-making in future leukemia clinical trials
  
• Pharmion And MethylGene Announce U.S. Orphan Drug Designation Granted For MGCD0103 For The Treatment Of Hodgkin's Lymphoma
  
• Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
  
• Pharmion announces acceptance of new drug application for azacitidine
  
• Pharmion Corporation (PHRM) announced the submission of a marketing authorization application with the European Medicines Agency (EMEA) for Thalidomide Pharmion for the treatment of untreated multiple myeloma in the European Union (E.U.)
  
• Pharmion Corporation (PHRM) announced the submission of a new drug application (NDA) supplement to add IV administration to instructions in the prescribing information for its demethylating agent Vidaza
  
• Phase 1 trial of SNS-595 in advanced leukemias demonstrates promising clinical activity
  
• Phase III Study of Rituxan in Leukemia Meets its Goal
  
• Philadelphia chromosome-positive leukemia treated with dasatinib
  
• Phosphatidylinositol-3 kinase (PI3K)/Akt inhibition promoted apoptosis in Hodgkin lymphoma (HL)
  
• Phosphatidylinositol-3 kinase (PI3K)/Akt inhibition promoted apoptosis in Hodgkin lymphoma (HL)
  
• Physical exercise as adjuvant therapy for patients undergoing hematopoietic stem cell transplantation
  
• Pioglitazone inhibits leukemia cell growth lines but not normal hematopoietic stem cells
  
• Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
  
• Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
  
• PKC-d (protein kinase C-d) was announced as a promising new target in chronic lymphocytic leukemia (CLL) treatment
  
• PKC-d (protein kinase C-d) was announced as a promising new target in chronic lymphocytic leukemia (CLL) treatment
  
• PKC-d (protein kinase C-d) was announced as a promising new target in chronic lymphocytic leukemia (CLL) treatment
  
• Plasticity in lymphangiogenesis regresses after the postnatal period
  
• Polymorphism Reduces Benefit of Bleomycin in Testicular Cancer
  
• Poor prognosis in pediatric acute myeloid leukemia (AML) was linked to KIT mutations, and not FLT3 internal tandem duplication
  
• Poor prognosis in pediatric acute myeloid leukemia linked to KIT mutations
  
• Possible Cause of Lymphoma Discovered
  
• Post-transplantation cytomegalovirus infection is addressed by attenuated poxvirus
  
• Postdoctoral Fellowship 2009-2010 -- Clinical Psychology
  
• Postdoctoral Fellowship 2009-2010 -- Clinical Psychology, Specializing in Adult Oncology and Bone Marrow Transplant
  
• Power Doppler ultrasound (US) scanning could be used to estimate bulky lymph nodes in Hodgkin lymphoma patients
  
• Power Doppler ultrasound (US) scanning could be used to estimate bulky lymph nodes in Hodgkin lymphoma patients
  
• Preclinical research supports Ceflatonin in treatment of acute myeloid leukemia
  
• Predicting Progression of Smoldering Multiple Myeloma
  
• Pregnancy among patients with chronic myeloid leukemia (CML) treated with imatinib was discussed
  
• Preharvest CD34+ count correlates with total number of collected CD34+ cells/kg
  
• Presence of FLT3 mutations does not impair stem cell mobilization
  
• Pretransplantation factors predict for treatment-related myelodysplastic syndrome after autologous stem cell transplantation
  
• Pretransplantation factors predict for treatment-related myelodysplastic syndrome after SCT
  
• Pretreatment cytogenetics could be used to help prognosticate older acute myeloid leukemia (AML) patients
  
• Pretreatment cytogenetics could be used to help prognosticate older acute myeloid leukemia (AML) patients
  
• Pretreatment cytogenetics could be used to help prognosticate older acute myeloid leukemia (AML) patients
  
• Primary cutaneous marginal zone B-cell lymphoma (PCMZL) was linked to aberrant nuclear B-cell lymphoma 10 (BCL10) expression, but not t(11;18)(Q21;q21) translocation
  
• Progenitor cell differentiation is stimulated by thrombin and protease-activated receptor-1
  
• Progress toward a targeted therapy for a specific form of leukemia
  
• Promyelocytic Blast Crisis of Chronic Myeloid Leukemia during Imatinib Treatment
  
• Proteasome inhibition is new therapy for non-Hodgkin lymphoma
  
• Proteasome inhibition is new treatment strategy in leukemia
  
• Proteasome inhibition with bortezomib is a new therapeutic strategy for non-Hodgkin lymphoma
  
• Protein kinase C-d announced as promising new target in chronic lymphocytic leukemia treatment
  
• Protein kinase C-d announced as promising new target in chronic lymphocytic leukemia treatment
  
• Proteolix closes $45 million financing to support expansion of clinical trials of PR-171
  
• Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
  
• Proteomic screening leads to early detection of acute GVHD after stem cell transplantation
  
• Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
  
• Quantitative Comparisons of Antibody-Binding Sites of Platelet Glycoprotein IIb/IIIa in Aplastic Anemia and Idiopathic Thrombocytopenic Purpura
  
• Quantitative PET Imaging Finds Early Determination of Effectiveness of Cancer Treatment
  
• Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study
  
• Quest Diagnostics launches tests to assess status of leukemia and lymphoma in using blood plasma
  
• Radiation Therapy for Prostate Cancer Increases Incidence of AML
  
• Rapid one-hour transduction of whole bone marrow leads to long-term repopulation of murine recipients with lentivirus-modified hematopoietic stem cells
  
• Rapid one-hour transduction of whole bone marrow leads to long-term repopulation of murine recipients with lentivirus-modified hematopoietic stem cells
  
• Rate of secondary cancers increases over years after treatment for childhood leukemia
  
• Rate of Secondary Cancers Increases Over Years After Treatment for Childhood Leukemia
  
• Rates of cutaneous T-cell lymphoma increase over 30 years
  
• Re-immunization with human T-cell leukemia virus type 1 (HTLV-1)-infected cells reduced HTLV-1 proviral loads in rats orally infected with HTLV-1
  
• Recent findings from University of Ulm highlight research in leukemia therapy
  
• Recent findings in leukemia provide new insights
  
• Recent research demonstrates the effectiveness of Thal/Dex therapy in treating multiple myeloma
  
• Recent research from Germany has documented the requirement of the human T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes
  
• Recent research from Germany has documented the requirement of the human T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes
  
• Recent research from Germany has documented the requirement of the human T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes
  
• Recent research from Germany has documented the requirement of the human T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes
  
• Recent research from the United States has reported on the clarification of transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia (T-ALL)
  
• Recent research from the United States has reported on the clarification of transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia (T-ALL)
  
• Recent research from the United States has reported that alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism
  
• Recent research from the United States published in the journal Blood has documented the independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia (AML) with a normal karyotype
  
• Recent studies from University of Oxford, Medical Research Council add new data to leukemia
  
• Receptor kinases in multiple myeloma submit to a new indolinone
  
• Recurrent Inactivation of the PRDM1 Gene in Primary Central Nervous System Lymphoma
  
• Refractory cytomegalovirus infection successfully treated after stem cell transplant
  
• Refractory or relapsed acute lymphoblastic leukemia treated by clofarabine
  
• Relapsed and refractory acute lymphoblastic leukemia (ALL) could not be treated by arsenic trioxide (AT)
  
• Remission of acute myelogenous leukemia (AML) with AML1/ETO rearrangement should be confirmed by FISH because granulocyte-colony stimulating factor (G-CSF) therapy could conceal residual malignant cells
  
• Report summarizes leukemia study findings from University of Limoges
  
• Report summarizes leukemia study findings from University of Limoges
  
• Report summarizes lymphoma study findings from General Hospital, Department of Pathology
  
• Reports from Multiple Myeloma Research Consortium describe recent developments
  
• Reports from Nagoya University add new data to research in acute promyelocytic leukemia risk factors
  
• Reports from Netherlands, Italy and Germany describe recent advances in leukemia research
  
• Reports from Quest Diagnostics Nichols Institute advance knowledge in myelodysplastic syndrome
  
• Reports from University of Bristol add new data to research in myeloma genetics
  
• Reports from University of Southampton, Cancer Sciences Division add new data to research in acute lymphoblastic leukemia in children
  
• Reports from University of Yamanashi, Department of Pediatrics describe recent advances in leukemia therapy
  
• Reports on leukemia findings from National Institute for Occupational Safety and Health provide new insights
  
• Reports outline chronic myeloid leukemia therapy research from Fred Hutchinson Cancer Research Center
  
• Reports outline chronic myeloid leukemia therapy research from Fred Hutchinson Cancer Research Center
  
• Reports outline myeloma therapy study findings from College of Medicine, Division of Hematology-Oncology
  
• Reports summarize acute myeloid leukemia therapy research from Johann Wolfgang Goethe University
  
• Reports summarize leukemia in children study results from Centers for Disease Control and Prevention
  
• Reports summarize leukemia research from University of Miami, Sylvester Comprehensive Cancer Center
  
• Reports summarize leukemia therapy study results from Cukurova University, Department of Oncology
  
• Reports summarize myeloid leukemia research from INSERM
  
• Reports summarize myeloid leukemia research from INSERM
  
• Research and Markets releases report on treatment options for chronic lymphocytic leukemia
  
• Research conducted at University of Saskatchewan has provided new information about leukemia
  
• Research data from Kumamoto University, Department of Neurology update understanding of amyloidosis
  
• Research findings from Cancer Research Center, Tongji Medical College update understanding of lymphocytic leukemia
  
• Research findings from Eskisehir Osmangazi University, Department of Pediatrics update understanding of acute lymphoblastic leukemia therapy
  
• Research findings from Ludwig-Maximilians University update understanding of aplastic anemia in children
  
• Research findings from Technion update understanding of myelocytic leukemia
  
• Research findings, "Complex secondary chromosome abnormalities in advanced stage anaplastic large cell lymphoma of children and adolescents
  
• Research findings, "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia," are discussed in a new report
  
• Research findings, "Distribution and clinicopathologic characteristics of non-Hodgkin's lymphoma in India: a study of 935 cases using WHO classification of lymphoid neoplasms (2000)," are discussed in a new report
  
• Research findings, "Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells," are discussed in a new report
  
• Research findings, "Hematopoietic progenitor cell deficiency in fetuses and children affected by Down's syndrome," are discussed in a new report
  
• Research findings, "Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia," are discussed in a new report
  
• Research from Alfred Hospital in the area of myeloma therapy published
  
• Research from College of Medicine, Division of Hematology yields new findings on acute myeloid leukemia therapy
  
• Research from Columbia University, Department of Medicine provide new insights into lymphoma genetics
  
• Research from Dongduk Women's University, Department of Applied Chemistry yields new findings on leukemia cell biology
  
• Research from Kaiser Permanente has provided new information about leukemia in children
  
• Research from National University of Singapore, Children's Medical Institute reveals new findings on acute myeloid leukemia in children
  
• Research from Saitama Medical University, Department of Internal Medicine has provided new information about leukemia therapy
  
• Research from Saitama Medical University, Department of Pathology provide new insights into myeloma
  
• Research from University Hospital has provided new data on leukemia
  
• Research from University Hospital has provided new information about lymphoma quality of care
  
• Research from University of Bonn, Department of Pediatric Hematology-Oncology provide new insights into leukemia in children
  
• Research from University of Heidelberg broadens understanding of chronic myeloid leukemia therapy
  
• Research from University of Rome provides new data on testicular cancer
  
• Research from Vanderbilt University, Department of Biochemistry yields new findings on leukemia gene therapy
  
• Research from Vanderbilt University, Department of Urologic Surgery provide new insights into testicular cancer in children
  
• Research in the area of acute myeloid leukemia reported from Hacettepe University, Department of Internal Medicine
  
• Research on experimental therapies detailed by scientists at Boston Medical Center
  
• Research on leukemia prevention discussed by scientists at University Federal do Ceara
  
• Research on leukemia prevention discussed by scientists at University Federal do Ceara
  
• Research on myeloproliferative disorders discussed by scientists at University of Arizona, Department of Pathology
  
• Research on testicular cancer therapy discussed by scientists at Lund University, Department of Oncology
  
• Research reports from Mackay Memorial Hospital, Department of Medicine provide new insights into acute myeloid leukemia therapy
  
• Research reports from Tongji University, Department of Pathology provide new insights into b-cell leukemia
  
• Research results from Electric Power Research Institute update understanding of leukemia
  
• Research results from University of Leicester, Department of Infection update understanding of myeloma vaccines
  
• Research shows cord blood comparable to matched bone marrow
  
• Researcher to Study Dog Genome for Clues to Lymphoma in Humans
  
• Researchers are studying a more persistent tolerance to islet allografts through bone marrow transplantation in minimal nonmyeloablative conditioning therapy
  
• Researchers at Institute of Experimental Medicine target myelocytic leukemia
  
• Researchers at Leiden University release new data on myelomonocytic leukemia genetics
  
• Researchers at Leiden University release new data on myelomonocytic leukemia genetics
  
• Researchers at Mayo Clinic Cancer Center have identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works
  
• Researchers at National Center for Epidemiology, Division of Virology target myeloma
  
• Researchers at National Institutes of Health target hairy cell leukemia therapy
  
• Researchers at Ohio State University have discovered that two microRNA (miRNA) molecules help control the oncogene responsible for a dangerous form of B-cell chronic lymphocytic leukemia (B-CLL), the most common human leukemia in the world
  
• Researchers at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia may have found a new way to sidestep the drug resistance that has limited the success of leukemia drug Gleevec
  
• Researchers at University Hospital publish new data on leukemia therapy
  
• Researchers at University of Alabama publish new data on chronic lymphocytic leukemia immunology
  
• Researchers at University of Sheffield publish new data on testicular cancer
  
• Researchers at Zhejiang University, Department of Ophthalmology publish new data on amyloidosis
  
• Researchers at Zhejiang University, Institute of Pharmacology and Toxicology have published new data on leukemia cell biology
  
• Researchers attempt to unlock the mystery of acute lymphoblastic leukemia
  
• Researchers describe recombinant, tumor-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas in a recent issue of Expert Opinion on Biological Therapy
  
• Researchers detail in "Epstein-Barr virus represses the FoxO1 transcription factor through latent membrane protein 1 and latent membrane protein 2A," new data in lymphoma
  
• Researchers detail in "HOX decoy peptide enhances the ex vivo expansion of human umbilical cord blood CD34+ hematopoietic stem cells/hematopoietic progenitor cells," new data in cord blood
  
• Researchers detail in "Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L," new data in cell biology
  
• Researchers detail in "Roles of DRB1 *1501 and DRB1 *1502 in the pathogenesis of aplastic anemia," new data in aplastic anemia
  
• Researchers detail in "The safety of central line placement prior to treatment of pediatric acute lymphoblastic leukemia," new data in neutropenia
  
• Researchers discover inherited mutation for leukemia
  
• Researchers Expand Natural Killer Cells In Cord Blood To Fight Leukemia
  
• Researchers from Columbia University describe findings in acute myeloid leukemia genetics
  
• Researchers from Copenhagen University report details of new studies and findings in the area of lymphoma therapy
  
• Researchers from Debrousse Hospital publish findings in acute myeloid leukemia in children
  
• Researchers from Erciyes University, Department of Hematology report details of new studies and findings in the area of acute lymphoblastic leukemia
  
• Researchers from Fox Chase Cancer Center report details of new studies and findings in the area of cell biology
  
• Researchers from Genentech, Inc. report recent findings in chronic lymphocytic leukemia immunology
  
• Researchers from Health Science Center report details of new studies and findings in the area of chronic lymphocytic leukemia
  
• Researchers from Health Science Center report details of new studies and findings in the area of chronic lymphocytic leukemia
  
• Researchers from Italy, the United States and Japan report details of new studies and findings in the area of leukemia
  
• Researchers from La Paz University, Department of Haematology publish findings in lymphoma therapy
  
• Researchers from Medical School discuss findings in t-cell leukemia immunology
  
• Researchers from Rambam Medical Center detail new studies and findings in the area of acute myeloid leukemia genetics
  
• Researchers from Roswell Park Cancer Institute describe findings in myeloma therapy
  
• Researchers from School of Medicine, Department of Medicine detail findings in chronic lymphocytic leukemia therapy
  
• Researchers from University of Michigan, Department of Pediatrics provide details of new studies and findings in the area of acute lymphoblastic leukemia
  
• Researchers from University of Milan, Department of Clinical Medicine publish findings in chronic myeloid leukemia
  
• Researchers from University of Texas, M.D. Anderson Cancer Center report recent findings in chronic myeloid leukemia therapy
  
• Researchers have identified enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia
  
• Researchers have identified enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia
  
• Researchers have identified enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia
  
• Researchers in South Korea have reported that deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia (CML)
  
• Researchers proposed the feasibility of treating chronic lymphocytic leukemia (CLL) by clofarabine on a weekly schedule
  
• Researchers publish findings on potential target for leukemia treatment
  
• Researchers Seek Alternative For Leukemia Patients Resistant To Standard Therapies
  
• Researchers shed light on mechanism of action used by anti-cancer drug
  
• Researchers stated that myeloid/natural killer (NK) cell precursor acute leukemia diagnosis does not require myeloid antigens
  
• Researchers stated that myeloid/natural killer (NK) cell precursor acute leukemia diagnosis does not require myeloid antigens
  
• Researchers study the spike in testicular cancer
  
• Researchers' work from Harvard University, Department of Mathematics focuses on chronic myeloid leukemia
  
• Researchers' work from University of Heidelberg, Department of Internal Medicine focuses on myeloma
  
• Researchers' work from University of Heidelberg, Department of Internal Medicine focuses on myeloma
  
• Response of childhood acute lymphoblastic leukemia (ALL) to chemotherapy could be predicted by caspase 8-associated protein 2 (CASP8AP2) expression
  
• Response of leukemia to chemotherapy improved by administering cyclosporin-A
  
• Response to chemotherapy in chronic myeloid leukemia (CML) patients could be evaluated by estimating lipid profile
  
• Retinal pigment epithelial cell infection with human T-cell leukemia virus type 1 is inhibited by an ICAM-1 neutralizing antibody
  
• Retrovirus-associated sequence (RAS)-blocking bisphosphonate zoledronic acid (ZOL) could be used to inhibit juvenile myelomonocytic leukemia (JMML) cells
  
• Revlimid (lenalidomide) survival data evaluated in previously treated multiple myeloma
  
• Revlimid data presented at ASCO stands to change the way physicians treat multiple myeloma
  
• Revlimid evaluated as combination oral treatment regimen in newly diagnosed multiple myeloma
  
• Revlimid Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
  
• Revlimid in combination with dexamethasone approved by U.S. Food and Drug Administration
  
• Revlimid(R) Clinical Study Reports Survival Advantage for Patients Newly Diagnosed With Multiple Myeloma at European Hematology Meeting
  
• RGD conjugation to polyethyleneimine does not improve DNA delivery to bone marrow stromal cells
  
• Richter's transformation of leukemia to diffuse large cell lymphoma detected by PET/CT
  
• Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
  
• Risk for Hodgkin lymphoma may be modifiable through strenuous physical activity
  
• Risk of leukemia with multiple sclerosis drug higher than thought
  
• Risk of lymphoma increases with hepatitis C virus infection
  
• Risk Of Second Cancers Greatest In Younger Patients Treated For Non-Hodgkins Lymphoma
  
• Rituxan® Maintenance in Follicular Lymphoma Deemed Cost-effective
  
• Rituximab maintenance therapy improves survival in patients with relapsed follicular lymphoma
  
• Rituximab Reverses Some Chemo Resistance in Lymphoma
  
• Roche's MabThera approved in Europe for CLL
  
• Rodent Stem Cells With a Human Touch
  
• Romidepsin Active for Treatment of Refractory Cutaneous T-Cell Lymphoma
  
• Sacroiliitis as an initial manifestation of acute myelogenous leukemia," is the subject of a report
  
• Salvage radiotherapy was deemed safe and effective for select patients with Hodgkin lymphoma after chemotherapy failure
  
• Schering-Plough Corporation reported that its antifungal agent NOXAFIL(R) (posaconazole) Oral Suspension received a category 1 recommendation for preventing certain invasive fungal infections (IFIs) in high-risk cancer patients
  
• SCID mouse model enables rapid evaluation of treatments for multiple myeloma
  
• Scientists at Erasmus University, Department of Haematology target myeloma prognosis
  
• Scientists at Genzyme Corporation target leukemia
  
• Scientists at Kobe University, Department of Pediatrics release new data on acute lymphoblastic leukemia therapy
  
• Scientists at Nagasaki Medical Center target arthritis
  
• Scientists at Nagoya City University report research in t-cell leukemia immunology
  
• Scientists at National Cancer Institute describe research in leukemia therapy
  
• Scientists at National Heart Lung and Blood Institute release new data on aplastic anemia immunology
  
• Scientists at National Institutes of Health, Department of Health and Human Services target testicular cancer risk factors
  
• Scientists at University Hospital target leukemia therapy
  
• Scientists at University Hospital target myeloma
  
• Scientists at University of Arkansas, Myeloma Institute for Research and Therapy publish research in myeloma genetics
  
• Scientists at University of California, Moores Cancer Center describe research in acute myeloid leukemia therapy
  
• Scientists at University of Kansas, Department of Microbiology release new data on t-cell leukemia therapy
  
• Scientists at University of Kansas, Department of Microbiology release new data on t-cell leukemia therapy
  
• Scientists at University of Oxford, Weatherall Institute of Molecular Medicine release new data on acute megakaryocytic leukemia in children
  
• Scientists at University of Versailles Saint-Quentin-en-Yvelines target acute myeloblastic leukemia therapy
  
• Scientists at Virginia Commonwealth University, Massey Cancer Center release new data on leukemia therapy
  
• Scientists at Yonsei University, Medical Research Center target acute myeloid leukemia prognosis
  
• Scientists claimed that attitude toward remission induction (RI) for elderly patients with acute myeloid leukemia (AML) influenced survival
  
• Scientists Discover New Molecular Markers for Testicular Cancer
  
• Scientists Discover New Role For microRNA In Leukemia
  
• Scientists discuss in "Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes" new findings in lymphoma
  
• Scientists evaluated the response of leukemia to dasatinib (BMS-354825)
  
• Scientists evaluated the response of leukemia to dasatinib (BMS-354825)
  
• Scientists found that hypoxia induces N-(4-hydroxyphenyl)-retinamide (Fenretinide, 4-HPR) resistance in leukemia cells
  
• Scientists found that seemingly normal circulating dendritic cell (DC) compartment carrying the Ph+ chromosome could be identified in chronic myelogenous leukemia (CML) patients
  
• Scientists from Panacea Pharmaceuticals, Inc. gave a presentation on the utility of gene expression of Human aspartyl (asparaginyl) Beta-hydroxylase (HAAH) as a biomarker to diagnose and monitor disease status in patients with acute myelogenous leukemia
  
• Scientists gain important insights into acute promyelocytic leukemia
  
• Scientists Gain Insight Into Blood Cancer's Progression
  
• Scientists have identified the key LMO2-binding determinants on Ldb1
  
• Scientists in the United States conducted a study that reported overexpression of the ETS-related gene (ERG) predicts a worse outcome in acute myeloid leukemia (AML) with normal karyotype
  
• Scientists insisted on the need for pediatric acute myeloid leukemia (AML) subtype-specific therapies to replace the outdated "one size fits all" strategy
  
• Scientists isolate leukemia causing stem cells in a mouse model of human leukemia
  
• Scientists outline the approval summary of nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma in a recent issue of Clinical Cancer Research
  
• Scientists suggest that abnormal phenotypic features typical of T-LGL leukemia may hold diagnostic value
  
• SCL relative LYL-1 required for fetal and adult stem cell function and B-cell differentiation
  
• Scoring system identifies MDS patients who have low-risk disease but a poor prognosis
  
• Scripps Research Institute, Department of Chemistry describes research in amyloidosis therapy
  
• SDF-1/CXCR4 axis promotes stem cell proliferation in contact with mesenchymal stem cells
  
• Seattle Genetics Announces Initiation of Phase Ib Clinical Trial of SGN-40 in Combination with Rituxan and Gemzar for Non-Hodgkin Lymphoma
  
• Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical Trial
  
• Seattle Genetics Completes Enrollment in Lintuzumab Phase IIb Clinical Trial for Patients with Acute Myeloid Leukemia
  
• Seattle Genetics focuses on trials
  
• Seattle Genetics Initiates Phase II Clinical Trial of SGN-40 for the Treatment of Non-Hodgkin's Lymphoma
  
• Seattle Genetics Initiates Phase IIb Clinical Trial of SGN-33 in Combination with Chemotherapy for Acute Myeloid Leukemia
  
• Seattle Genetics Initiates SGN-40 Clinical Trial in Combination with Revlimid for Multiple Myeloma
  
• Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
  
• Seattle Genetics reports data encouraging on lymphoma-targeting monoclonal antibody
  
• Seattle Genetics, Inc. (SGEN) announced that it has initiated a phase I clinical trial of SGN-35 for patients with Hodgkin disease and other CD30-positive hematologic malignancies
  
• Seattle Genetics, Inc. (SGEN) reported data from its ongoing phase 2 clinical trial of SGN-30 in cutaneous anaplastic large cell lymphoma (ALCL) and other lymphoproliferative disorders
  
• Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SGN-33 for the treatment of acute myeloid leukemia (AML) and to SGN-35 for the treatment of Hodgkin's disease
  
• Second gene linked to familial testicular cancer
  
• Semafore granted nearly $1 million to study small molecule SF1126 in multiple myeloma
  
• Semafore Pharmaceuticals, Inc. announced receipt of a grant award from the Multiple Myeloma Research Foundation (MMRF) for a phase l trial evaluating its Pl3K inhibitor SF1126 in multiple myeloma
  
• September Is National Leukemia and Lymphoma Awareness Month
  
• Seven genes monitor minimal residual disease in pediatric acute myeloid leukemia
  
• Several factors affect bone marrow volume reduction and red blood cell depletion prior to transplant
  
• Severe acute graft-versus-host disease-related costs and survival rates increasing
  
• Severe infections cause nonrelapse mortality after unrelated donor stem cell transplantation
  
• Sexual function affected by stem cell transplant according to long-term study
  
• SGX Pharmaceuticals and Novartis collaborate on BCR-ABL inhibitors for chronic myelogenous leukemia
  
• SGX Pharmaceuticals discontinues clinical trial of Troxatyl in acute myelogenous leukemia
  
• SGX Provides Update on BCR-ABL Collaboration
  
• shRNA expression in CD34+ progenitors avoids induction of siRNA interferon responses
  
• Silencing a protein could kill T-Cells, reverse leukemia
  
• Silencing of secreted frizzled-related proteins (SFRPs) by CpG island methylation may activate Wnt signaling in chronic lymphocytic leukemia (CLL)
  
• Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
  
• Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
  
• Single-agent bortezomib demonstrated biologic activity in fludarabine-refractory B-cell chronic lymphocytic leukemia (CLL) patients
  
• Single-dose pegfilgrastim induces stem cell mobilization in malignant lymphoma or multiple myeloma
  
• Smaller white-matter volumes were linked to deficits in neurocognitive performance among long-term survivors of acute lymphoblastic leukemia (ALL)
  
• SNDA filed for bortezomib compound for injection in treating relapsed mantle cell lymphoma
  
• Society Presents Free October Program on Childhood Leukemia and Lymphoma
  
• Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
  
• Somatic hypermutation (SHM) is linked to leukemia via its alteration of B cell receptor (BCR) autoreactivity
  
• Some adult chronic myeloid leukemia patients respond poorly to imatinib
  
• Some adult chronic myeloid leukemia patients respond poorly to imatinib and may therefore favor allogeneic stem cell transplantation
  
• Some blood-system stem cells reproduce more slowly than expected
  
• Sonographic Features of Liver Involvement by Lymphoma
  
• Sparing leukemia patients from unnecessary chemo
  
• Spectrum Pharmaceuticals, Inc. Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
  
• Spicy Pickle(TM) Teams With Leukemia & Lymphoma Society In 'Hike For Discovery' Fundraiser On July 18
  
• St. Jude develops follow-up test to identify children with acute lymphoblastic leukemia
  
• St. Jude discovery offers new avenues to understanding an aggressive form of leukemia
  
• St. Jude finds anti-leukemia drug increases patient fatigue
  
• St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
  
• St. Jude finds mechanism for faulty protein disposal in Multiple Myeloma
  
• St. Jude finds more than 100 gene variations linked with response to leukemia treatment
  
• St. Jude researchers explore link between treatment for immune disorder and development of leukemia
  
• St. Jude researchers explore link between treatment for immune disorder and development of leukemia
  
• St. Jude researchers identify key genetic trigger of acute myeloid leukemia
  
• Staging and follow-up of pediatric lymphomas could be conducted with F-18 FDG-PET imaging
  
• Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma
  
• Stem cell and myoblast cotransplantation improves ventricular function in Chagas disease
  
• Stem cell apheresis prediction method generates accurate and immediate yield predictions
  
• STEM CELL PROCEDURE SUCCESSFULLY TREATS AMYLOIDOSIS PATIENTS
  
• Stem cell subtypes discovered by BC Cancer Agency
  
• Stem Cell Transplant May Improve Survival Among Elderly with Relapsed Non-Hodgkin’s Lymphoma
  
• Stem cell transplant postremission improves high-risk acute lymphoblastic leukemia survival
  
• Stem Cell Transplant Procedures Vary Throughout the World
  
• Stem cell transplantation cures anhidrotic ectodermal dysplasia-related immunodeficiency
  
• Stem cell transplantation increases survival in some patients with advanced multiple myeloma
  
• STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
  
• Stem cell transplantation timing from last chemotherapy affects lymphocyte collection
  
• Stem Cell Transplants from Unrelated Donors Effective for Younger Patients with AML with Adverse Cytogenetics
  
• Stem cells derived from adult testes produce wide range of tissue types
  
• Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
  
• Stem cells make bone marrow cancer resistant to treatment
  
• Stem cells may look malignant, not act it
  
• Stem cells suppress lymphocyte proliferation in vitro, do not prevent graft-versus-host disease
  
• Steroid myopathy common with high-dose steroid therapy after stem cell transplant in AML/MDS
  
• Strategies for treating multiple myeloma by osteoblast suppression were described
  
• STRESS HORMONE MAY HASTEN THE PROGRESSION OF CERTAIN BLOOD CANCERS
  
• Structural and functional ciliary abnormalities common in stem cell transplantation recipients
  
• Students Raise $18 million to Fight Blood Cancer
  
• Studies at cancer conference show new therapies are changing the outlook for blood cancer patients
  
• Studies attribute recent increase in multiple myeloma survival to novel therapies
  
• Studies from Cancer Institute, Division of Hematology have provided new information about acute myelogenous leukemia
  
• Studies from College of Medicine, Department of Dermatology reveal new findings on amyloidosis
  
• Studies from Dana-Farber Cancer Institute, Department of Medical Oncology in the area of chronic lymphocytic leukemia genetics published
  
• Studies from Duke University further understanding of chronic lymphocytic leukemia genetics
  
• Studies from Federal University describe new findings in lymphoma in children
  
• Studies from M.D. Anderson Cancer Center, Department of Leukemia add new findings in the area of myelodysplastic syndrome therapy
  
• Studies from M.D. Anderson Cancer Center, Department of Leukemia have provided new data on leukemia
  
• Studies from Martin-Luther University, Center for Cell and Gene Therapy provide new data on leukemia gene therapy
  
• Studies from Mount Sinai School of Medicine, Department of Human Genetics have provided new information about acute myeloid leukemia therapy
  
• Studies from Nagasaki University, Department of Neurosurgery provide new data on acute lymphoblastic leukemia therapy
  
• Studies from National Heart, Lung, & Blood Institute update current data on myelocytic leukemia therapy
  
• Studies from Ramathibodi Hospital, Faculty of Medicine yield new data on acute lymphoblastic leukemia in children
  
• Studies from Research Center further understanding of acute lymphoblastic leukemia in children
  
• Studies from Saitama Children's Medical Center, Division of Hematology yield new data on acute lymphoblastic leukemia in children
  
• Studies from University Medical Center provide new data on leukocyte biology
  
• Studies from University of Copenhagen, Department of Haematology reveal new findings on myeloma immunology
  
• Studies from University of Perugia, Italy, advance leukemia knowledge
  
• Studies from University of Rio Grande, Health Science Center describe new findings in acute lymphoblastic leukemia
  
• Studies from University of Ulm yield new information about amyloidosis therapy
  
• Studies in the area of leukemia therapy reported from Azabu University, Institute of Bioscience
  
• Study Analysis: High Percentage of Blood Disorder Patients Were Cured or Achieved Remission When Treated with Stem Cells from Their Own Cord Blood or a Sibling’s
  
• Study analyzes heart attack mortality risk associated with Hodgkin disease treatments
  
• Study data from Brandeis University, Rosenstiel Basic Medical Sciences Research Center update understanding of leukemia genetics
  
• Study data from China Medical University, Graduate Institute of Pharmaceutical Chemistry update knowledge of leukemia therapy
  
• Study data from China Medical University, Graduate Institute of Pharmaceutical Chemistry update knowledge of leukemia therapy
  
• Study data from National Human Genome Research Institute provide new insights into acute myelogenous leukemia
  
• Study data from Peking University, Department of Chemical Biology provide new insights into myelocytic leukemia prevention
  
• Study data from Royal Manchester Children's Hospital update knowledge of leukemia in children
  
• Study data from Sapporo Medical University provide new insights into myeloma cell biology
  
• Study data from Sidney Kimmel Cancer Center update knowledge of chronic myelogenous leukemia
  
• Study data from University of Sao Paulo, Department of Biochemistry and Molecular Biology update understanding of acute lymphoblastic leukemia risk factors
  
• Study findings from Centers for Disease Control and Prevention broaden understanding of leukemia
  
• Study findings from Keio University provide new insights into acute promyelocytic leukemia therapy
  
• Study findings from Shanghai Jiao Tong University, Shanghai Institute of Hematology provide new insights into leukemia cell biology
  
• Study findings from University of Medicine and Dentistry of New Jersey provide new insights into acute myelogenous leukemia
  
• Study findings from University of Sao Paulo, Hematology Division broaden understanding of chronic lymphocytic leukemia
  
• Study findings from Zhejiang University, Institute of Hematology broaden understanding of myelodysplastic syndrome cell biology
  
• Study finds heart failure is rare among leukemia patients on imatinib
  
• Study identifies the molecular process underlying leukemia
  
• Study of Leukemia Survivors Gives Hints for Better Care
  
• Study refutes recent report that bone marrow can replenish female oocytes
  
• Study results from Antoni van Leeuwenhoek Hospital, Division of Immunology provide new insights into oncology
  
• Study results from Beckman Research Institute broaden understanding of leukemia
  
• Study results from Children's Hospital, Pathology Department in the area of lymphoblastic lymphoma in children published
  
• Study results from Cleveland Clinic Foundation provide new insights into myeloid leukemia cell biology
  
• Study results from Dana-Farber Cancer Institute update understanding of leukemia
  
• Study results from Dartmouth University, Department of Biochemistry update understanding of leukemia genetics
  
• Study results from Erasmus University, Department of Immunology provide new insights into residual neoplasms therapy
  
• Study results from Fudan University, Division of Hematology-Oncology broaden understanding of acute lymphoblastic leukemia in children
  
• Study results from German Cancer Research Center broaden understanding of b-cell lymphoma immunology
  
• Study results from Harvard Cancer Center provide new insights into myelodysplastic syndrome
  
• Study results from Karolinska University, Karolinska Institute in the area of testicular cancer epidemiology published
  
• Study results from Ludwig-Maximilians University, Department of Hematology in the area of acute myeloid leukemia therapy published
  
• Study results from Ohio State University, Comprehensive Cancer Center in the area of acute myeloid leukemia prognosis published
  
• Study results from Shanghai Jiao Tong University, Shanghai Institute of Hematology update understanding of leukemia
  
• Study results from Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Urology provide new insights into testicular cancer risk factors
  
• Study results from Tokyo Medical and Dental University in the area of myelodysplastic syndrome genetics published
  
• Study results from University of Bristol, Bristol Institute for Transfusion Sciences update understanding of acute lymphoblastic leukemia
  
• Study results from Walther Cancer Institute broaden understanding of acute myeloid leukemia immunology
  
• Study shows Revlimid patients live longer and remain transfusion free
  
• Study shows Sprycel achieved higher cytogenetic responses, longer survival than Gleevec
  
• Study shows that maintenance rituximab is useful for advanced indolent lymphoma
  
• Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
  
• Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
  
• Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
  
• Surgery Earlier In Life Reduces Risk of Testicular Cancer Among Males with Undescended Testis
  
• Survival improved for children requiring intensive care after bone marrow transplant
  
• Survival in chronic lymphocytic leukemia (CLL) could be predicted by lipoprotein lipase (LPL) expression
  
• Survival of second testicular cancer not lower
  
• Survival of transformed lymphocytes requires human T-cell leukemia virus gene
  
• Survivin overexpression and sodium arsenite could induce apoptosis in adult T-cell leukemia (ATL)
  
• Survivors of childhood leukemia and brain tumors are more at risk for strokes later in life
  
• Survivors of Testicular Cancer at Increased Risk of Death from Other Causes
  
• SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232) Closed and Patients Given Choice to Switch to REVLIMID(R) Plus Dexamethasone
  
• Symptoms of Non-Hodgkin's Lymphoma
  
• Synergy between cyclin D2 and CKS1B genes may lead to early multiple myeloma treatment failure
  
• Syracuse University researchers discover new way to attack some forms of leukemia
  
• T cell acute lymphoblastic leukemia downstream regulatory networks clarified
  
• T cell acute lymphoblastic leukemia/lymphoma target identified
  
• T cell receptor transduced into primary human lymphocytes
  
• T cell-mediated rejection of allografts overcome using T-regulatory cells
  
• T cells are suppressed in a mediated fashion in B-cell non-Hodgkin lymphoma
  
• T-cell non-Hodgkin lymphomas (NHLs) could be linked to high expression of FMNL1 protein
  
• T-cell non-Hodgkin lymphomas (NHLs) could be linked to high expression of FMNL1 protein
  
• T-cell non-Hodgkin lymphomas (NHLs) could be linked to high expression of FMNL1 protein
  
• T-cell therapy for adenovirus infection post-transplantation has advantages, limitations.
  
• Takara Bio to supply RetroNectin for gene therapy clinical trials of multiple myeloma
  
• Targeted therapies for CML: practical considerations and comparisons
  
• Targeting Leukemia Cell's Gene 'addiction' Presents New Strategy For Treatment
  
• Targets of aberrant hypermethylation identified in myeloid leukemia
  
• Tasigna receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
  
• Tasigna Recommended for European Approval to Treat Rare Form of Leukemia No Longer Responding to Glivec
  
• Tasigna(R) approved in Switzerland based on impressive efficacy in patients with a form of leukemia no longer responding to Glivec(R)
  
• Tasigna(R) receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
  
• Terminal loss of heterozygosity (LOH) occurred without loss of genetic material in acute myeloid leukemia
  
• Testicular cancer and relation to space-time clustering examined
  
• Testicular cancer development not caused by azoospermic factor deletions
  
• Testicular cancer gauge often not used
  
• Testicular cancer incidence increasing and mortality declining in 22 European countries
  
• Testicular cancer patients undergo therapeutic drug monitoring for cisplatin dose individualization
  
• Testicular cancer risk is not associated with adolescent BMI, but is associated with height
  
• Testicular cancer risk is not related to adolescent BMI but is related to height
  
• Testicular Cancer Therapy Affects Risk of Second Malignancies and CVD
  
• Testicular Cancer Therapy Affects Risk of Second Malignancies and CVD
  
• Testicular Chromosome Structure and Gene Expression Will Provide an Opportunity to Analyze Male Reproductive Biology and the Processes by Which Sperm Are Formed
  
• Testicular Microlithiasis - Our Experience of 10 Years
  
• Testis cancer management by retroperitoneal lymph node dissection discussed
  
• Tetanus vaccine strategies must be different for low- and high-risk leukemia groups
  
• TGen, collaborators launch Multiple Myeloma Genomic Initiative research program
  
• Thalidomide analogue-induced neutropenia in multiple myeloma is linked to increase in neutrophils bearing CD64
  
• Thalidomide analogue-induced neutropenia in multiple myeloma is linked to increase in neutrophils bearing CD64
  
• Thalidomide delays disease progression in newly diagnosed multiple myeloma, study shows
  
• Thalidomide improves myeloma survival in elderly
  
• Thalidomide plus dexamethasone is effective in newly diagnosed multiple myeloma
  
• Thalidomide Plus Dexamethasone: Improved Primary Myeloma Therapy
  
• Thalidomide plus standard therapy improves survival in patients with multiple myeloma
  
• Thalomid® in Induction Improves Progression-free Survival in Elderly with Myeloma
  
• The biology of mucosa-associated lymphoid tissue (MALT) lymphoma was discussed
  
• The Biomarkers Consortium Web site launched for concept submissions and possible funding
  
• The CML Society of Canada's newly launched website receives important recognition from the American Society of Hematology
  
• The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
  
• The FLT3 D324N variant may be associated with a predisposition to different subtypes of leukemia, according to a study from Germany
  
• The frequency of chronic lymphocytic leukemia (CLL) expressing V(H)1-69 was low in Japanese patients
  
• The genetics of MLL leukemogenesis
  
• The IMF says journal editorial documents dramatic increase in survival since the 1980s
  
• The inhibition of mTOR could be a potential treatment option for anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)
  
• The inhibition of mTOR could be a potential treatment option for anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)
  
• The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML
  
• The Leukemia & Lymphoma Society Announces Appointment Of New Chief Medical Officer
  
• The Leukemia & Lymphoma Society Offers Program on Chronic Lymphocytic Leukemia
  
• The loss of tumor protein 53 (TP53) in B-cell chronic lymphocytic leukemia (B-CLL) could be due to the absence of nearly the entire chromosome 17 p-arm
  
• The loss of tumor protein 53 (TP53) in B-cell chronic lymphocytic leukemia (B-CLL) could be due to the absence of nearly the entire chromosome 17 p-arm
  
• The molecular effects of all-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) have been elucidated
  
• The Multiple Myeloma Research Consortium (MMRC) and Keryx Biopharmaceuticals (KERX) announced the initiation of a multicenter phase 1 clinical program to explore the oral combination
  
• The Multiple Myeloma Research Consortium (MMRC) and Proteolix initiate Phase 2 clinical trial investigating Carfilzomib for the treatment of Multiple Myeloma
  
• The Multiple Myeloma Research Consortium (MMRC) announced that four additional academic institutions have joined its innovative research model
  
• The Multiple Myeloma Research Consortium (MMRC) announced the launch of the Multiple Myeloma Genomic Initiative, a multimillion dollar research program designed to rapidly accelerate progress made against multiple myeloma by significantly improving the un
  
• The Multiple Myeloma Research Consortium and Nereus Pharmaceuticals Initiate Clinical Trial Investigating NPI-0052 to Treat Multiple Myeloma
  
• The Multiple Myeloma Research Consortium and Nereus Pharmaceuticals Initiate Clinical Trial Investigating NPI-0052 to Treat Multiple Myeloma
  
• The Myeloma Landscape in 2008
  
• The optimal use of cytogenetics in the diagnosis and management of lymphomas was discussed
  
• The origins of the Cancer Control and Health Outcomes Committee within the Cancer and Leukemia Group B (CALGB) were recounted
  
• The outcome of myeloma was not improved with the addition of PSC-833 (valspodar) to vincristine, doxorubicin, and dexamethasone (VAD)
  
• The outcome of pediatric acute myeloid leukemia (AML) could be impacted by patient age, implying that children younger than 10 years might benefit more than older children from newer, intensive therapies
  
• The pathogenesis of childhood acute lymphoblastic leukemia (ALL) could be linked to PTPN11 mutation
  
• The pathogenesis of childhood acute lymphoblastic leukemia (ALL) could be linked to PTPN11 mutation
  
• The prognosis of chronic lymphocytic leukemia (CLL) was not affected by the presence of familial trait
  
• The radiologic morphology of low-grade primary central nervous system lymphoma (PCNSL) was described
  
• The risk of acute myeloid leukemia (AML) associated with treatments for Hodgkin lymphoma was assessed
  
• The risk of childhood acute lymphoblastic leukemia (ALL) was linked to methyletetrahydrofolate reductase (MTHFR) C677T polymorphism in Greek patients
  
• The risk of non-Hodgkin lymphoma (NHL) could be affected by diet
  
• The risk of non-Hodgkin lymphoma is not associated with use of hormone replacement therapy
  
• The risk of non-Hodgkin lymphoma is not associated with use of hormone replacement therapy
  
• The risk of relapse and death in children with acute myeloid leukemia (AML) after induction therapy could be predicted by high expression of Wilms tumor gene 1 (WT1)
  
• The risk of relapse and death in children with acute myeloid leukemia (AML) after induction therapy could be predicted by high expression of Wilms tumor gene 1 (WT1)
  
• The unexpected connection of two gene regulation mechanisms points to new ways for the fight against leukemia
  
• The use of risk-adapted therapy for acute myeloid leukemia (AML) patients was discussed
  
• The Virtual Leukemia Cup Regatta is Launched!
  
• Theralux ATIR may be feasible strategy for mismatched stem cell transplantation
  
• Therapeutic angiogenesis falls short in ischemic limbs deprived of CD34-positive cells
  
• Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model
  
• Three molecular triggers threaten leukemia patients
  
• Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
  
• Tipifarnib May Benefit Certain Patients with Refractory or Relapsed AML
  
• Total parenteral nutrition in hematopoietic stem cell recipients was related to hyperglycemia
  
• TRAIL apoptotic pathway mediates inhibitor induced leukemia cell apoptosis
  
• Trakya University, Department of Hematology publishes research in lymphoma
  
• Trakya University, Department of Hematology publishes research in lymphoma
  
• Transduction of cytotoxic T lymphocytes may be safe for cancer treatment
  
• Transient leukemia in neonates with Down syndrome characterized
  
• Transplanted bone marrow cells fail to adopt a pancreatic beta-cell fate
  
• Transplanted bone marrow-derived stem cells have potential to migrate to cochlea
  
• Transplanted human stem cell rejection does not involve natural killer cells
  
• Transporter expression profiled in childhood T cell acute lymphoblastic leukemia
  
• Treating male infertility with stem cells
  
• Treatment concepts of acute promyelocytic leukemia (APL) were discussed
  
• Treatment for Chronic Myelogenous Leukemia
  
• Treatment outcomes improved in neonatal leukemia in Japan
  
• Treatment shows combination therapy leads to long-term remission in follicular non-Hodgkin's lymphoma
  
• Treatment shows combination therapy leads to long-term remission in follicular non-Hodgkin's lymphoma
  
• Treatment strategies for young children with acute lymphoblastic leukemia (ALL) that avoid cranial radiation therapy (CRT) are associated with good long-term neurocognitive outcomes
  
• Treatment strategies for young children with acute lymphoblastic leukemia (ALL) that avoid cranial radiation therapy (CRT) are associated with good long-term neurocognitive outcomes
  
• Treatment-related mortality substantial during stem cell transplant for systemic AL amyloidosis
  
• Trial to evaluate custom vaccine for chronic lymphatic leukemia initiated by M.D. Anderson
  
• Trichostatin A could improve anticancer activity of low concentrations of curcumin in leukemia
  
• Triple purge strategy eliminates chronic myelogenous leukemia cells from autografts
  
• Triptolide displayed potent antileukemic activity
  
• Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
  
• Tumor angiogenesis is limited by promyelocytic leukemia tumor suppressor
  
• Tumor Necrosis Factor Antagonists Not Linked to Significant Risk of Malignant Lymphoma Compared With Other RA Treatments
  
• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was proposed as an anticancer agent in acute myeloid leukemia (AML)
  
• Tumor proliferation and angiogenesis increase in response to mesenchymal stem cells
  
• Two Novel Biologics Studied for Multiple Myeloma
  
• Two step approach for follicular non-Hodgkin Lymphoma found effective
  
• U of M begins nation's first clinical trial using T-reg cells from cord blood in leukemia treatment
  
• U-M study finds lymphoma drug effective over long term
  
• U.S. FDA approves Sprycel (dasatinib) with two indications
  
• U.S. FDA Approves Velcade + Doxil Combination for Treatment of Relapsed/Refractory Multiple Myeloma
  
• U.S. FDA approves Velcade for injection for aggressive form of non-Hodgkin lymphoma
  
• U.S. FDA gives rapid approval for new treatment for chronic myeloid leukemia
  
• UCLA researchers discover genes linked to lymphoma that may open way for new targeted drugs
  
• UCSD Launches Vaccine Trial for Chronic Lymphocytic Leukemia
  
• UCSD researchers identify potential new drug target for chronic leukemia
  
• UCSF faculty receive $13.7 million from CIRM for stem cell research
  
• Umbilical Cord Blood Adds Graft Options in Childhood Leukemia
  
• Umbilical cord blood banks highly variable in assessing graft characteristics
  
• Umbilical cord blood is as good as bone marrow in treating leukemia
  
• University of California researchers report new molecule that targets leukemia and lymphoma cells
  
• University of California researchers report new molecule that targets leukemia and lymphoma cells
  
• University of Massachusetts research shows benefits of Revlimid treatment in MDS patients
  
• University of Montreal reports research in myelodysplasia therapy
  
• University Of Pittsburgh Discovers Genetic 'Shut Down' Trigger In Healthy Immune Cells
  
• University of Sao Paulo publishes research in chronic lymphocytic leukemia
  
• Unrelated cord blood transplantation feasible in adults with high-risk malignancy
  
• Unrelated cord blood transplantation is an alternative for adults with hematological malignancies lacking an HLA-matched donor
  
• Unrelated cord blood transplantation is an alternative for adults with hematological malignancies lacking an HLA-matched donor
  
• Unrelated mismatched umbilical cord blood transplantation successfully treats an infant with malignant infantile osteopetrosis
  
• Unrelated umbilical cord blood transplantation is feasible in adults with high-risk malignancy
  
• Unstable leukemia stem cells may predispose patients to drug resistance
  
• Updated REVLIMID(R) Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia
  
• UR doing world's first trial of pill targeting lymphoma
  
• USC researchers find benefit for lymphoma patients in combined PET-CT scanning
  
• USC researchers identify tumor suppressor that manages cellular cleaning and recycling proceses
  
• Vaccination with idiotypic protein or DNA failed to prolong dormancy in mice with BCL1 lymphoma
  
• Vaccine May Improve Cancer-free Survival for Follicular Lymphoma
  
• VAD-Doxil-Thalomid Confirmed Better than VAD-Doxil for Myeloma
  
• Valproic acid (VPA) and all-trans retinoic acid (ATRA) were used to treat patients with poor-risk acute myeloid leukemia (AML)
  
• Valproic acid (VPA) was deemed clinically useful in low-risk myelodysplastic syndrome (MDS)
  
• Varicella zoster virus meningitis occurred following BMT despite valaciclovir prophylaxis
  
• VELCADE(R) (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
  
• Velcade® plus Perifosine Shows Promise in Relapsed or Refractory Multiple Myeloma
  
• Ventura named Director of Leukemia & Lymphoma Society
  
• Vertebral compression fractures caused by multiple myeloma treated by vertebroplasty
  
• Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data
  
• Veto cells may be used for tolerance induction without graft-versus-host disease
  
• ViaCell completes phase 1 trial of potential therapy for stem cell transplant candidates
  
• Video Game Hero Crash Bandicoot Urges Kids to Join the Fight Against Leukemia
  
• Vion Announces Suspension of Phase III Trial in Relapsed AML
  
• Vion Pharmaceuticals (VION) Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
  
• Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
  
• Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine
  
• Vion Pharmaceuticals proceeds to second stage of phase 2 trial of cloretazine in elderly AML
  
• Vion Pharmaceuticals proceeds to second stage of phase 2 trial of cloretazine in elderly AML
  
• Virginia Commonwealth University Massey Cancer Center researchers have identified an approach to enhance the activity of a new anti-cancer agent that has already shown impressive efficacy in the treatment of chronic myelogenous leukemia
  
• Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells
  
• Warnex announces an exclusive licence with Ipsogen to market a leukemia molecular diagnostic service in Canada
  
• Washington University scientists first to sequence genome of AML patient
  
• Wilmot Cancer Center Scientist gets $1.5M to Advance Lymphoma Research
  
• With Help from Mother Nature: A Novel New Drug Discovery May Revolutionize Treatment of Inflammatory Diseases and Leukemia
  
• World Marrow Donor Association guidelines for use of HLA nomenclature and its validation in the data exchange among hematopoietic stem cell donor registries and cord blood banks
  
• World's Top Cancer Research Body Sponsors Landmark COLD-FX(R) Trial
  
• XANTHUS ANNOUNCES ORAL FLUDARABINE NDA ACCEPTED FOR REVIEW BY U.S. FDA
  
• Xanthus Completes Special Protocol Assessment with FDA for Phase 3 Registration Trial of Xanafide in Patients with Secondary Acute Myeloid Leukemia
  
• Xanthus licenses late-stage oral fludarabine for lymphocytic lymphoma from Schering AG
  
• Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML
  
• Xanthus receives orphan drug designation of Xanafide for treating acute myeloid leukemia
  
• Xencor Initiates Phase I Clinical Trial with XmAb2513 in Lymphoma
  
• Xencor to Present New Data from Anti-CD19 Antibody Program at ASCO
  
• Xenomics announces development of test for genetic marker for acute myeloid leukemia
  
• Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
  
• Xenomics Announces License With Asuragen for NPM1 Leukemia Diagnostics
  
• Young single men are more likely to bank sperm before testicular cancer treatment
  
• Younger donor age associated with better stem cell transplantation outcome
  
• ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
  
• Zoledronate was shown to induce apoptosis in imatinib-resistant chronic myeloid leukemia (CML) cells
  

Events

• Family Member and Caregiver Support Group
  
• Leukemia and Lymphoma Society Family Support Groups
  
• Young Adult Support Group
  

Glossary

• Ablative Transplants
  
• Afebrile
  
• ALL
  
• Allogeneic Transplant (Allo)
  
• Alopecia
  
• AML
  
• ANC (Absolute Neutrophil Count)
  
• Anemia
  
• Antibiotics
  
• Antiemetic
  
• Antimicrobial
  
• Apheresis
  
• Arterial Blood Gas (ABG)
  
• Ascites
  
• Aspirate
  
• Autologous Transplant (Auto)
  
• Biologic Therapy
  
• Biopsy
  
• Blast Crisis
  
• Blood Chemistry Studies
  
• Blood Immunoglobulin Studies
  
• Blood Transfusions
  
• Blood Typing & Cross-Matching
  
• Bone Marrow (BM)
  
• Bone Marrow Aspiration and Biopsy
  
• Bone Marrow Transplant (BMT)
  
• Bone Marrow Transplantation
  
• Candida
  
• Carcinoma In Situ
  
• CAT or CT Scan (Computed Tomography Scan)
  
• CD34+
  
• Central Venous Catheter (CVC)
  
• Chemotherapy
  
• Chest X - Ray (CXR)
  
• Clinical Trial
  
• CLL
  
• CML
  
• Conditioning Regimen
  
• Cord Blood Stem Cells
  
• Core Biopsy
  
• Cryopreservation
  
• Culture
  
• Cytogenetic Analysis
  
• Cytomegalovirus (CMV)
  
• Cytoxan® (CTX or CY)
  
• Day 0
  
• Differential (diff)
  
• DLCO
  
• Donor Cell Infusion (DCI)
  
• Donor Lymphocyte Infusion
  
• Electrolytes (lytes)
  
• Electrophoresis
  
• Emesis
  
• Engraftment
  
• Estrogen or Progesterone Receptor Test
  
• Etoposide
  
• Excisional Biopsy
  
• Familial (or Hereditary) Amyloidosis
  
• FDA
  
• Febrile
  
• Foley Catheter
  
• Gallium Scan
  
• Germ Cell Tumors
  
• GI tract
  
• Graft Versus Host Disease (GVHD)
  
• Graft Versus Malignancy or Leukemia
  
• Granulocytes
  
• Growth Factor Drugs
  
• Growth Factors
  
• Harvest
  
• Hematocrit (crit, Hct)
  
• Hematology
  
• Hematuria
  
• Hemmorrhagic Cystitis
  
• Hemoglobin (Hgb)
  
• Herpes Simplex Virus (HSV)
  
• High-Dose Chemotherapy
  
• High-Dose/Myeloablative Regimens
  
• HLA Typing (Human Leukocyte Antigen Typing)
  
• Hodgkin Lymphoma
  
• Hormone Therapy
  
• Immunophenotyping
  
• Immunosuppressive Therapy
  
• Incisional Biopsy
  
• Infertility
  
• Intrathecal Chemotherapy
  
• Irradiation
  
• Liver Function Tests (LFTs)
  
• Low Microbial Diet (LMD)
  
• Lymph Node Biopsy
  
• Lymphatic Tissue
  
• Lymphocytes
  
• Male Hormones
  
• Mammogram
  
• MDS
  
• Metastatic
  
• MM
  
• Mobilization (priming)
  
• Monoclonal Antibodies
  
• Monocytes
  
• MRI (Magnetic Resonance Imaging)
  
• Mucositis
  
• MUD (Matched Unrelated Donor Transplant)
  
• Needle Biopsy or Fine-needle Aspiration Biopsy
  
• Neutropenia
  
• NHL
  
• Non-myeloablative transplant (reduced intensity; mini-allogeneic)
  
• Oncologic Drug Advisory Committee Meeting (ODAC)
  
• Oncologic Drugs Advisory Committee (ODAC)
  
• Oncology
  
• P/SL
  
• Packed Red Blood Cells (PRBC)
  
• Palliative Therapy
  
• Pancytopenia
  
• Patient Controlled Analgesic (PCA)
  
• Performance Score
  
• Perineum (Perineal Area)
  
• Peripheral Blood
  
• Peripheral Stem Cell Transplants
  
• Perirectal
  
• PET Scan (Positron Emission Tomography)
  
• Philadelphia Chromosome
  
• PICC
  
• Plasmapheresis
  
• Platelet (PLT)
  
• Platelets
  
• Pluripotent Stem Cell
  
• Prophylactic
  
• Protocol
  
• Psychosocial
  
• Pulmonary Function Tests (PFTs)
  
• Radiation Therapy
  
• Randomization
  
• Red Blood Cell (RBC)
  
• Reduced Intensity
  
• Reed-Sternberg Cells
  
• Relapse
  
• Related Donor
  
• Respiratory Syncytial Virus (RSV)
  
• Restaging
  
• RMCC
  
• SAA
  
• Secondary Amyloidosis
  
• Secondary Testicular Tumors
  
• Solid Tumor
  
• Staging
  
• Staging Laparotomy
  
• Stem Cell
  
• Stem Cell Transplant
  
• Stem Cell Transplantation
  
• Stereotactic Body Radiation Therapy
  
• Stomatitis
  
• Stromal Tumors
  
• Syngeneic Transplant
  
• Thoracentesis
  
• Thrombocytopenia
  
• Total Body Irradiation (TBI)
  
• Total Parental Nutrition (TPN)
  
• Transfusion Therapy
  
• Treatment Guidelines
  
• Tumor Lysis Syndrome
  
• Tyrosine Kinase Inhibitor
  
• Unrelated Donor (URD Transplant)
  
• URI
  
• Watchful Waiting
  
• White Blood Cell (WBC)
  
• Xerostomia
  

Our Physicians

• Scott I. Bearman, MD
  
• Mark W. Brunvand, MD
  
• Michael B. Maris, MD
  
• Jeffrey V. Matous, MD
  
• Peter A. McSweeney, MD
  

Our Team

P/SL Medical Center

Rocky Mountain Cancer Centers

Becoming a Donor

Donations

Volunteering

Resources

• American Cancer Society
  
• American Society of Hematology
  
• Amyloidosis Support Group
  
• Amyloidosis Support Network
  
• Aplastic Anemia and MDS International Foundation
  
• Cancer Care, Inc
  
• Center for International Bone Marrow Transplant Registry (CIBMTR)
  
• Cutaneous Lymphoma Foundation
  
• European Hematology Association (EHA)
  
• Fred Hutchinson Cancer Research Center
  
• Institute for Myeloma & Bone Cancer Research (IMBCR)
  
• International Myeloma Foundation
  
• International Waldenstrom's Macroglobulinemia Foundation
  
• Lance Armstrong Foundation (LAF)
  
• Leukemia Research Foundation
  
• Living with Lymphoma
  
• Lymphoma Information Network
  
• Lymphoma Research Foundation
  
• Multiple Myeloma Research Consortium (MMRC)
  
• Multiple Myeloma Research Foundation
  
• National Bone Marrow Transplant Link
  
• National Cancer Institute
  
• National Marrow Donor Program
  
• People Living with Cancer
  
• The European Group for Blood and Marrow (EBMT)
  
• The Leukemia and Lymphoma Society
  
• The Myelodysplastic Syndromes Foundation
  
• The Wellness Community
  

Contact Us

Search